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ABSTRACT 
Paediatric pharmacology is a neglected area in terms of rational use of drugs. Wide 
differences have been observed in children’s exposure to drugs between and within 
countries and regions. The aim of the current thesis is to investigate the determinants of 
drug prescription in paediatrics. Pharmacoepidemiology and the use of administrative 
databases can be a useful tool for this scope. 
Data collected in regional and multiregional administrative prescription databases were 
analysed. Prevalence data by sex and age were calculated by dividing the number of drug 
users by the total number of male and female residents in each age group. Univariable and 
multivariable analyses were performed with the aim to identify the determinants of drug 
prescriptions. 
The studies showed quantitative and qualitative differences in drug prescription to children 
and adolescents among Italian regions and within regions. The prescription of a great 
number of different, redundant, active substances, even among experienced paediatricians, 
was found. A North-South trend was found in antiasthmatic and antibiotic prevalence, with 
an important association with average income at the area level. A confirmation of the high 
prevalence of these drugs and poor qualitative profile was also found.  
Large heterogeneity was found in psychotropic drug prevalence among different Italian 
regions. Psychotropic drugs were scantly prescribed and some of the most used drugs were 
prescribed off-label. The analyses of the prescription of generic antibiotics showed that 
generic formulations are scantly prescribed by Italian paediatricians, and the lowest 
prescription rate of generic drugs was found in paediatricians who prescribe more 
antibiotics. Some quality indicators for antibiotic prescribing were developed at the 
paediatrician level. The youngest paediatricians and those who were not exposed to 
educational interventions showed a significantly worse quality of prescribing. The thesis 
provide some useful data for policy makers in order to improve the rational drug use in 
children. 
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1. Background 
Improving the rational use of drugs and the use of health care resources are important 
research topics in the public health field, even in western countries [1]. The World Health 
Organization estimated that half of the prescriptions filled worldwide are inappropriate [2]. 
Children are among the most exposed to drugs, with an estimated prevalence of 60% in 
western countries [3]. This population of patients is also inherently one of the most fragile, 
hence inappropriate treatments should be avoided as much as possible. 
In the literature, qualitative and quantitative differences have been found in the 
prescription of drugs to children between and within countries, and even in the same 
regions, showing that patterns of use are largely heterogeneous even within the same 
geographic setting [3-6]. According to available data, the prescription rates of drugs in 
children in western countries range from 0.8 in Norway (1988-89) to 3.2 prescriptions per 
per child in USA (1992-93) with large heterogeneity also in the methodological aspect of 
studies[3]. Large differences in antibiotic exposure (the most used drug class among 
children) between countries have been found. An Italian child has, on average, a fourfold 
higher risk of being exposed to antibacterial drugs than an English child and a threefold 
higher risk than a Dutch child, with increased prescription rate of second choice antibiotics 
[4]. Wide differences have been observed also in children’s exposure to anti-asthmatics 
between different countries: prevalence ranges from 6.2% in Norway to 19% in Italy [5].  
The heterogeneity found, however, does not seem to be related to differences in disease 
epidemiology but, in most cases, to inappropriate use [7,8]. For example, cephalosporins, a 
second line treatment in most paediatric infections, are widely prescribed in Italy, while in 
the Netherlands and Denmark this class is hardly prescribed [4]. Also, in Italy, the use of 
inhaled steroids, such as beclometasone, is threefold and fourfold higher than in UK and in 
the Netherlands, respectively, because such treatments are prescribed in nebulised 
formulations in Italy mainly as symptomatic treatment of upper respiratory tract infections 
(URTI) [5, 9-11]. 
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The determinants of inappropriate use or over-prescription are many and complex. Some 
have been studied in depth, such as the FP’s attitude to prescription [12]. The most 
important factors linked to the family paediatricians’ (FP) over-prescription are diagnostic 
uncertainty and perceived parental expectations of a prescription [13]. The existing 
healthcare system and patient- or parent-related sociocultural and economic determinants 
may also, however, be responsible for geographic differences in prescription profiles [14]. 
These associations have been described, but have been studied to a limited extent. For 
example, there is recent evidence that children receiving a high quantity of antibiotics 
belong to families that use more drugs in general [15]. Another study found that children 
receiving a psychotropic drug had a higher chance of having a family member with a 
psychiatric disorder [16]. There is evidence that children receiving hypnotic prescriptions 
were more likely to have mothers who receive hypnotic prescriptions  themselves, 
implicating that mothers were able to somehow influence the prescribing process [17]. It is 
not, however, understood how the socio-cultural and health status of the families can 
influence drug use in children. 
The use of healthcare databases to conduct retrospective studies is an important research 
tool concerning drug and health resources use. In fact data linkage of healthcare databases 
permits the assessment of large populations, it is flexible in design, has high speed of use, 
and avoid issues such as selection biases that are typical of other investigation tools like 
surveys or non-randomized ad hoc studies [18]. The use of real world-data that are 
routinely collected during the course of health care delivery can be a cost saver in respect 
to large RCTs for answering relevant epidemiological questions [19]. The important 
limitations of the healthcare databases available for use in this thesis will be discussed in 
the Methods section. 
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2. Previous drug utilisation studies at our laboratory 
In the past years the Laboratory for Mother and Child Health have produced a number of 
studies concerning drug utilisation, including reviews of the literature, and studies on the 
rational use of drugs in paediatrics. In this section I will summarize some of the main 
findings that are relevant to this thesis. 
a. Studies concerning any drug 
A review of the literature found that the prevalence of any kind of drugs in paediatrics 
ranged between 51% in Denmark to 70% in Greenland and the prescription rate ranged 
from 0.8 in Norway to 3.2 prescriptions per person in the United States [3]. The review also 
found large heterogeneity in the methodological quality and outcomes reported.  
A study investigated the drug prescription profile in the Lombardy Region and found a 
prevalence ranging between 38.4 and 54.8%. Drug prevalence was not correlated to 
hospitalization rate in the paediatric population. Being younger (1-5 years old), and living in 
the eastern part of the region were the factors associated with the highest risk of drug 
exposure [20].  
A more recent study investigated the prevalence of drug prescription in three Italian 
regions finding large differences among Local Health Units – LHUs - (ranging from 43.1% to 
70.0%), with an increased chance to receive a prescription in the South of the country [8]. 
Finally, a study investigated the differences in prescribing between GPs and FPs finding that 
children cared for by GPs had an higher chance to receive any drugs compared to those 
cared for by FPs [21]. 
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b. Studies concerning antibiotics 
A review of the literature found quantitative and qualitative differences in the antibiotic 
prescription profile between and within countries. Moreover, differences were found also 
at the local level and between prescribers. In general, second-choice antibiotic drugs were 
more commonly prescribed in settings characterised by a high prevalence of antibiotic 
prescription [4]. 
A study on seven Italian regions found that prevalence ranged from 42.6% to 62.1% among 
regions, and at the LHU level they ranged from 35.6% to 68.5%. There was a trend 
indicating that in southern regions antibiotics were more frequently prescribed than in the 
northern and central regions. Overall, penicillin covered 53.1% of antibiotic prescriptions, 
with differences between regions ranging from 39.2% to 62.5% with a North-South trend 
[6]. 
Another study on the Lombardy Region (the region with the highest population density in 
Italy, accounting for 1/6 of the Italian population) compared the prescription profile of a 
group of FPs that has been involved in initiatives concerning care for years with that of the 
others FPs in the region [22]. The study found a better qualitative profile in the FPs involved 
in educational initiatives. The study also found that by improving prescribing 
appropriateness (i.e. by increasing amoxicillin prescription), it would have been possible to 
reduce the expenditure associated with antibiotic prescriptions to outpatient children by 
about one-fifth [22].  
c. Studies concerning antiasthmatics 
A review of the literature found that the overall prevalence of antiasthmatics was 13.3%, 
and wide differences were found between countries, ranging from 6.2% in The Netherlands 
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to 19.0% in Italy [5]. The review found an heterogeneous quality of the studies in respect to 
the outcome measures reported [5]. 
A study on an Italian LHU found a prevalence of 12%, with high proportion of users being 
occasional (58%). The study found that the prevalence of anti-asthmatic prescription was 
much higher than prevalence of disease, indicating that anti-asthmatics were over-
prescribed. High use of nebulized steroids, mainly prescribed only once in a year, was 
found, supporting the hypothesis that they were prescribed not for asthma but as a 
symptomatic treatment of URTIs [23]. The study recently prompted a RCT on the 
effectiveness of nebulised beclomethasone in preventing viral wheezing [24]. The study 
showed that nebulised beclomethasone is not effective in preventing recurrence of viral 
wheezing, nor in reducing symptoms of respiratory tract infections, showing that its use for 
these indications is not evidence-based [24]. 
Most of the antiasthmatics prescribed in Italy are not used for asthma but for the 
treatment of symptoms of common URTI without rodust evidence of efficacy. Thus, a 
method of assessing asthma prevalence in a children population starting from prescription 
data was validated in a more recent study, by considering only pressurised formulations of 
antiasthmatics [25].  
d. Studies concerning psychotropic drugs 
A review of the literature found an increase in psychotropic drugs among paediatric 
patients in different countries in the past decade [26]. This increase was especially evident 
for stimulants and selective serotonin reuptake inhibitors. The analysis of the 
epidemiological data suggested that the risk of inappropriate use or abuse of these drugs 
was high [26]. 
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A study conducted in a LHU of the Veneto Region showed that the prevalence of 
prescription of psychotropic drugs was low in the 2004-2008 period compared to other 
countries, and the incidence slightly increased from 7.0 in 2005 to 8.3 per 10,000 children in 
2008 [16]. Despite the low prevalence, most children receiving a pharmacological 
treatment were not cared for by child and adolescent psychiatric services [16]. 
A successive study in the Lombardy Region found that 59,987 youths (37.1‰) attended a 
child and adolescent neuropsychiatry service at least once, but only 2,761 (1.7 ‰) received 
a pharmacological treatment, confirming the low use of psychotropic drugs compared to 
other countries [27]. Also in this study 57% of the youths who received a pharmacological 
treatment did not attend a child neuropsychiatry service [27]. 
3. Summary of the thesis 
This thesis is an attempt to evaluate the determinants of drug prescription in children in 
more detail. 
For doing so, the first part of the thesis is aimed at exploring the literature concerning the 
association between parents and child drug prescription and/or use. The aim of this review 
was to focus on a neglected area in terms of determinants of drug use, and this is an area 
that is potentially important but that was not investigated before in my laboratory. A 
systematic review of the literature was performed with the aim to collect  the studies and 
the results of epidemiological studies that used administrative databases that evaluated the 
association between drug use or prescription in parents and their offspring.  
The rest of the thesis focuses on studies performed using administrative databases. The 
first part focuses on some determinants of antibiotic, antiasthmatics, and psychotropic 
medicine prescriptions in large multiregional studies, which involved up to half of the 
children and adolescents Italian population, and are quite representative of the different 
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socio-cultural and geographical heterogeneity. In this first part the determinants of the 
prevalence of prescription of this drug classes was evaluated in respect to the geographical 
and income factors. 
In the last part of the thesis an evaluation on the quality of drug prescription and on the 
associated determinants, was performed with three studies. The first study was performed 
in collaboration with a group of experienced FPs involved in educational activities since 
2004. We collected information about the overall drug prescribed by this group in two 
consecutive months, and estimated a list of the most commonly prescribed “essential” 
drugs in the context of daily clinical practice in Italy. The other three studies employed the 
Lombardy Region administrative databases, the first study regarded the prescription of 
generic and brand name formulations of antibiotic in the clinical practice. The high 
prescribing paediatricians were found more likely to prescribe a brand name antibiotic than 
the low prescribing colleagues. 
In the second study proxy of safety and effectiveness were evaluated for the brand name 
and generic antibiotic, finding no differences both in the rate of recurrent prescription 
following a brand name versus generic prescription, and in the rate of hospital admissions. 
Finally the last study evaluated the quality of FPs’ antibiotic prescriptions by testing two 
newly identified indicators of quality of prescribing at the FP level. These indicators were 
elaborated starting from the epidemiology of the infectious diseases and some 
epidemiological data concerning the reasons for access to ambulatory care for the most 
common bacterial RTI in the Lombardy Region. The determinants of the quality of antibiotic 
prescribing was investigated in respect to a number of FP characteristics such as sex, age, 
number of patients, geographical factor, being an high or low prescriber. 
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II. Aims 
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The main aims of the project were: 
1. To evaluate the determinants of drug prescriptions in a large Italian out-patient 
paediatric population by using administrative databases. 
2. To compare the prescribing patterns in different settings, at different levels 
(national, regional, local) 
3. To monitor drug prescription patterns and the quality of therapies by evaluating 
their adherence to international treatment guidelines 
4. To estimate the quality of drug prescription in different settings, and in respect to 
different topics, including the prescription of generic antibiotics versus brand name 
drugs. 
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III. Methods 
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A. Pharmacoepidemiology 
Pharmacoepidemiology is defined as the study of the use and effects/side-effects of drugs 
in large numbers of people with the purpose of supporting the rational and cost-effective 
use of drugs in the population and thereby improving health outcomes [28]. 
Pharmacoepidemiology is strictly associated with large health care databases, and big data 
are often used to address research questions within pharmacoepidemiology. In fact this 
disclipline was born in 1960s togheter with the availability of large healthcare databases. 
Pharmacoepidemiology, with appropriate methodologies, can be a useful tool for  
improving the effectiveness and efficiency of healthcare interventions [28,29]. Such 
improvements may be of particular relevance in the paediatric population, since limited 
information on the safety and efficacy of drugs used in paediatrics still exists, despite the 
regulatory effort at the European and global levels [30-33]. Drug utilization studies in 
children may be used to identify the major therapeutic problems in this population. 
Moreover, although rational drug therapy is important for all individuals being treated with 
drugs, it is of paramount importance for children.  
B. Databases for healthcare research  
While administrative data are not designed for research, have limitations, are often difficult 
to access, and the linkage required between certain databases may be unfeasible, yet they 
retain a great research potential. The Administrative Data Taskforce identified the following 
items of value associated with the use of administrative data [34,35]: 
- The data already exist. There are no additional data collection costs associated with 
research use; 
- The data are typically large datasets, permitting more detailed research to be 
undertaken then would otherwise be the case; 
- The data records a process, which can be documented and understood; 
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- Linkage between data relating to different time periods can create longitudinal 
resources; and 
- Linkage to other data sources (e.g. surveys) can enhance these resources. 
Additionally health databases can provide data on diagnosed diseases through hospital 
admission and surgical procedures codes. The information on prescribed drugs, with 
appropriate techniques and integrations, can be used to estimate the prevalence of certain 
diseases, also in the outpatients [36]. 
 
C. The Italian NHS 
Italian healthcare is provided free or at a nominal charge through a network of 20 Regions 
and 101 LHUs (on 7 March 2017). Every Italian resident is registered with a family 
(paediatric or general) practitioner. Children are assigned to a FP until they are 6 years old; 
afterwards, the parents can choose to register a child with a GP. At 14 years old all 
adolescents are assigned to a GP. In Italy a national formulary is available, in which drugs 
are categorised into three classes: class A includes essential drugs that patients do not have 
to pay for, class C contains drugs not covered by the NHS, class H contains drugs 
administered only to inpatients that are fully reimbursed, and OTC drugs. Italian 
outpatients receive class A prescriptions from FPs, GPs, or other specialists and then get the 
medicines free of charge from retail pharmacies. Outpatients receiving prescriptions in 
community pharmacies and get the medicines free of charge through their GP 
prescriptions, or their FP prescriptions if they are children. Each local pharmacy provides 
these prescriptions to the Regional Health Authority to get reimbursed. The majority of 
drugs marketed for serious conditions are fully or partly reimbursed with only a few 
exceptions.  
A class A drug need to be prescribed by a GP or FP using a dedicated form to be reimbursed 
by the NHS. A specialist such as a neurologist or otorhinolaryngologist, does not necessarily 
use the NHS form when prescribing reimbursable class A drugs. Moreover, the NHS form 
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cannot be used for private visits. After a visit by a specialist, parents therefore go to their FP 
to obtain reimbursable prescriptions. 
 
D. The Lombardy Region 
The Lombardy Region is a large Italian region in the North of the country accounting for 1/6 
of the Italian population, with a total of 1,676,730 (2017) resident children and adolescents.  
The region was composed of 15 LHUs and 95 healthcare districts until the reorganisation in 
2016, when the LHUs were reduced to 8 (called ATS), and the healthcare districts to 27 
(called ASST), figure 1. The region is among the most wealthy in Italy, and it has an 
heterogenous geography, with a large plain area in the central and southern part, and 
mountains in the northern part. The region is very densly abitated and mostly composed of 
urban areas, with few rural areas. 
Almost all the studies presented in this thesis used the old administrative organisation, only 
the last study at chapter VI.D used the new one. 
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Figure 1 - Lombardy Region’s geographical location and administrative organisation
 
 
E. Healthcare databases 
1. Reimbursed prescription database 
The database contains reimbursable prescriptions (class A) routinely acquired for 
administrative and reimbursement reasons in the Lombardy Region. The database stores all 
community (i.e. outside hospital) prescriptions issued to individuals living in Lombardy 
Region. Within this system, a unique patient code prevents double counting of individuals 
who have been prescribed drugs by more than one physician. Each prescription is 
associated with a unique code identifying the medicine prescribed (including dosage and 
formulation). Other information available are: the prescription date, the number of boxes 
prescribed, and the prescriber and his/her characteristics. 
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2. Hospital discharge form database 
Besides prescription data, this database contains the hospital admissions of patients 
classified according to the ICD-9 system [37]. The relevant information available are 
concerning the patients’ vital statistics (age, sex, and address of residence); characteristics 
of the hospital stay (institute, ward and unit, type of admission, length of stay, priority) and 
clinical characteristics (primary diagnosis, other secondary diagnoses, diagnostic and 
therapeutic procedures, date of admission, discharge, or in-hospital death). Drugs 
administered during the hospital stay are not included in this database. Secondary 
diagnoses are up to to five co-existing conditions that may or may not be pre-existent.  
 
3. Specialist visits database 
Information about the outpatient specialist visits, in particular prescriptions for diagnostic 
tests, specialist visits, and rehabilitation performed in outpatient ambulatories are recorded 
for each resident patient. 
 
Since these three databases share the same unique patient identifier - through the Patient 
Record Database (which contains each patient’s vital statistics) - prescriptions, hospital 
admissions and specialist visits can be linked straightforwardly. The three databases are 
provided to our laboratory (Laboratory for Mother and Child Health) within the EPIFARM 
project, a pharmacoepidemiological project running since 2003 in agreement with the 
Regional Health Ministry of the Lombardy Region Data are available for these databases 
since 2000. The quality and accuracy of data is routinely checked and validated each year 
ensuring high standards, in particular more than 99% of the patients’ records were able to 
be linked among the three databases in 2011 Anonymity of each patient is granted by a 
third party society, that is not involved in any way in the analyses of the data, and that 
provide the laboratory with the data already encrypted within the unique patient identifier. 
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The other regions participating in the studies A and B, chapter V have a very similar 
structure of regional databases. 
 
F. Strength and limitations of these databases and available data 
The main advantage of monitoring the prescriptions dispensed by all the physicians to an 
entire population in a specific region. Because of the universal coverage of Italian NHS, 
there are not bias for the exclusion of children with different familiar socio-economic 
status, or concerning the prescription of more costly drugs, like it is the case in other 
countries. Moreover, data are available for a long time period, and this allow longitudinal 
studies in paediatric patients. 
The main limits are that private practice physicians, over-the-counter drugs, and drugs not 
reimbursed by the NHS are not included. However private practice drug prescription are 
quite limited. Among the most important paediatric drugs that are not recorded in the 
database there are paracetamol, ibuprofen, antiemetic drugs and most dermatologic drugs. 
Other limitations are that the therapeutic indication is lacking, and that it is not possible to 
know if the patient actually took the drug. Moreover, information concerning the socio-
economic status or the educational level of the individuals are not available. In order to 
overcome this issue, in some of the studies, average annual income at the area level was 
used as a proxy to the socio-economic status of individuals and families. 
In large databases very small differences between groups can result in statistically 
significant differences which are not clinically meaningful. Also, even if data quality is 
routinely checked in terms of matching among different databases, there are possible 
missings or incomplete data in some of the variables which need to be checked for each 
study. The eventual exclusion of some of the patients for missing variables needs to be 
evaluated in order to check if a selection bias is likely to occur for each study. 
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G. Synopsis of the characteristics of the studies 
Observation period and the study population varied depending on the different studies. 
Table 1 summarises the main indicators (source, age group, sample size) of the studies 
presented in this thesis. 
Table 1 - Characteristics of the pharmacoepidemiologic studies presented in the thesis 
Chapter Drug Year Source Age (ys) Sample size 
V.A antibiotics and 
antiasthmatics 
2008 Lombardy, Lazio, 
Puglia 
<18 1,861,425 
V.B psychotropic 
drugs 
2007-
2011 
Veneto, 
Lombardy, Friuli 
Venezia Giulia, 
Emilia Romagna, 
Abruzzo, Lazio, 
Puglia 
<18 5,019,564 
VI.A all 2012 Lombardy <14 64 FPs 
VI.B antibiotics 2008 Lombardy <13 1,276,932 
VI.C antibiotics 2010 Lombardy <18 1,669,856 
VI.D antibiotics 2011 Lombardy <14 1,164 FPs and 
424,280 children 
 
Differences in the sample chosen were due to different reasons, in part contingent (e.g. the 
availability of the data during the PhD project period), and in part due to the pattern of 
drug use. For example, in evaluating the pattern of anti-asthmatic or psychotropic drug 
prescriptions adolescents should also have been included, also in the case of studies that 
focused on FPs only children less than 14 years old where considered. 
The most recent available data were analysed when performing each study. 
H. Identification of drug prescriptions and patients 
Prescribed drugs were classified according to the International Anatomic-Therapeutical-
Classification system (ATC), which identifies the active substances. The formulations and 
dosage of the different active substances were identified through a univocal nine digits 
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code (MINSAN code). Patients were identified by using the anonymous patient identifier 
previously described, which prevents double counting of individuals who have been 
prescribed drugs by more than one physician 
I. Definitions and endpoints 
Proportion: the ratio of a specific quantity to the whole. Can be expressed as a percentage 
(i.e. the proportion of patients treated with a drug on the overall sample) 
Ratio: a relationship between two quantities indicating how many times the first contains 
the second 
Rate: the ratio between two related quantities (speed is a rate i.e number of meters per 
seconds), in epidemiology for example the number of prescriptions per year is a rate, and it 
is usually expressed per patient or per 100, 1000 patients. 
When referring to prevalence in this thesis the measure to be considered is period 
prevalence (annual prevalence), calculated by sex and age by dividing the number of drug 
users by the total number of male and female residents in each age group. A person 
receiving at least one drug in a year is defined drug user. Point prevalence is the proportion 
of persons with a particular attribute on a particular date, and will not be used in this 
thesis. Incidence is defined as the proportion of persons receiving a prescription (new 
cases) in a certain period of time (usually at least one year) considering the population 
initially at risk. In order to evaluate pharmaceutical consumption, the number of packages 
of medications (cartons) was used as an indicator of the whole drug exposure during the 
considered period. In fact, it can be related to the same medicine prescribed repeatedly or 
to different medicines. The rate of hospitalisation was estimated considering hospital 
discharge forms, by dividing the number of patients <18 years old hospitalised at least once 
during the observation period by the total number of residents < 18 years old. 
L. Statistical analyses 
Arithmetic mean and standard deviation or, when appropriate, medians and interquartile 
ranges, was used to summarise continuous variables, and the t test and Wilcoxon signed-
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rank tests to make comparisons among two samples. χ2 and χ2 for trend were used as 
appropriate for univariable comparisons of dichotomous data. Multivariable logistic 
regression was used in order to estimate risk factors increasing the probability of a given 
outcome. 
More details concerning the statistical analyses are provided in each chapter. The results of 
the statistical analysis are reported in this manner: test used; degree of freedom (d.f.); p-
value. 
Statistical analysis was performed using SAS software, version 9.2 to 9.5, and the 
cartographic representations and spatial analyses with ArcMap 10.5. 
A P value < 0.05 was considered statistically significant. 
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IV. Review of the literature 
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A. Drug use or prescription in parents and offsprings: a review of the literature 
 
1. Introduction 
A study on 50 families in 1980 published on the BMJ showed that children of mothers 
classed as high psychotropic users received twice as many antibiotics as the children of the 
mothers who had received no psychotropic medication [38]. 
A few recent studies showed that one of the possible determinants of drug prescription in 
children may be the amounts of drug used within his or her family [15,17]. A study in our 
laboratory previously showed that a child receiving a psychotropic drug had an higher 
chance of having a family member with a psychiatric disorder [16], indicating that 
prevalence of severe psychiatric disorders may be higher among youths whose parents 
have these disorders. Nevertheless, one of the two studies showed that a number of 
different drug classes were more used in parents of children receiving more antibiotics, 
without an apparent reason [15]. The authors hypothesised that, besides an inherited 
higher chance of developing a disease, parents' medicine use may influence that of children 
medicine prescription or use in other ways.  
In order to verify if other studies found that parent’s medicine use may influence that of 
children, and which type of drugs have been studied, I performed a systematic review of 
the pharmacoepidemiologic studies that investigated this topic. 
 
2. Search strategy 
A bibliographic search was performed in the MEDLINE (1966 - August 2017) and EMBASE 
(1966 - August 2017) databases. The search strategy included studies that investigated and 
quantified the association between offsprings and parental drug utilisation/prescription. In 
particular pharmacoepidemiological and epidemiological studies, including case-control, 
retrospective, longitudinal, prospective, and cross-sectional studies were included. The 
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search was limited to studies published before the 01/09/2017, to the mesh term 
“humans”, and published in English language. 
The base search performed contained the following mesh terms and keywords in the title 
and abstract:  
(drug utilization[Mesh] OR drug utilization[tiab] OR drug prescriptions[Mesh] OR drug 
prescription*[tiab] OR self medication[Mesh] OR self medication[tiab] OR medicin*[tiab]) 
AND (child[Mesh] OR children[tiab] OR infant[Mesh] OR infant*[tiab] OR newborn[Mesh] 
OR newborn*[tiab] OR adolescent[Mesh] OR adolescent*[tiab] OR pediatrics[Mesh] OR 
pediatric*[tiab] OR childhood[tiab]) 
 
This strategy found 40,674 results in pubmed and 55,329 results in Embase.The search 
strategy was further restricted to those studies including maternal or parental informations 
and to epidemiological observational type of studies. The following mesh and keywords in 
the title and abstract were employed: 
(mother*[tiab] OR mothers[Mesh] OR father*[tiab] OR maternal[tiab] OR paternal[tiab] OR 
parents[Mesh] OR parent[tiab] OR parents[tiab]) AND (epidemiologic studies[Mesh] OR 
epidemiologic[tiab] OR pharmacoepidemiology[Mesh] OR pharmacoepidemiolog*[tiab] OR 
pharmaco-epidemiolog*[tiab] OR case-control[tiab] OR retrospective[tiab] OR cohort[tiab] 
OR longitudinal[tiab] OR prospective[tiab] OR cross-sectional[tiab]). 
After this step 1620 studies were retrieved in Pubmed and 2844 in Embase. Since the 
search strategy was very broad we excluded the following category of studies by using 
relevant mesh terms and key words: 
- editorials, commentaries, case reports, guidelines and lectures; 
- studies about congenital abnormalities and birth defects; 
- studies about illicit substance abuse, addictive behaviour and other substance- 
 related disorders; 
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- studies about the vertical transmission of infectious diseases and mother-to-
 child transmission of  other diseases;    
- studies about inpatients, conducted in hospitals, in intensive care unit or 
 concerning surgical  procedures; 
- studies concerning alternative or traditional medicine or complementary 
 therapies; 
 
In order to restrict the search to those studies that investigated an association between the 
variables studied, we further refined the search by using the following key words as free 
text in the articles' titles and abstracts: association*, associated, relation*, prediction*, 
correlation*, determinant*, factor*, comparison*, compare*, influence*. After the 
bibliographic search a total of 150 studies were found in Medline database, and 228 studies 
were found in the Embase database. A total of 33 studies were duplicates, thus the number 
of unique studies retrieved was 345. The titles and abstracts of the studies retrieved were 
read, and a total of 7 relevant studies were identified. The full text of the selected studies 
was screened, and a manual search of bibliographies was also conducted to identify 
additional pertinent studies. The only 1980 study on 50 families was excluded in order to 
have a more homogeneous sample of studies in respect to sample size and year of 
publication. Finally, six studies were included in the review, Figure 2. The PRISMA guideline 
was partially followed for this study, besides the fact that an appropriate checklist was not 
found for this kind of studies. 
All the references have been collected and analysed using the software Reference 
Manager, version 11 (Institute for Scientific Information, Berkeley, California).   
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Figure 2 – Study selection 
 
                         Embase                                        Medline 
     228          150 
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                                                      Duplicate studies 33 
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                                                                      After title and abstract screening 338  
                       were not relevant 
   
7 
             The 1980 study on 50 families  
    was excluded   
              6 
 
 
3. Data extraction 
The following data were extracted and tabulated from each study: type of study (e.g. 
retrospective, prospective, survey, etc..), number of subjects included, age of children, 
which drug class was investigated, the statistical methods, topic of the study (relevant to 
the review), the quantification of the outcome of interest. The included studies were too 
heterogeneous to permit meta-analysis. Therefore, we qualitatively synthetized the results 
according to endopoints of interest. 
 
4. Results  
a. Characteristics of studies 
Out of 345 studies initially identified six studies were selected. Five out of six studies were 
from North-Europe (two from Norway, one from Denmark, Finland, The Netherlands) and 
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one study was from Brazil. Three study were surveys (two cross-sectional and one part of a 
prospective study), and three were retrospective cohort studies using prescription and visit 
databases as data sources. All the included studies were published after 2010. The total 
sample size ranged from 131 to 97.574. The studies included children from widely different 
age ranges, Table 2 (ordered by the class of drugs investigated, starting from the studies 
investigating all drug classes).  
Table 2 – Characteristics of the studies 
Author Year Type of study Country Number 
of 
subjects 
Age Topic of interest Significant 
association 
found 
De Jong 2012 Retrospectic 
cohort 
(database) 
The 
Netherlands 
6,731 ≤5 Parental chronic 
prescription of drugs (at 
least three times per 
year), and recurrent 
antibiotic prescription vs 
no use of antibiotics (until 
five years old) in the 
children 
Yes, but not 
with all the 
drug classes 
studied 
Hameen
-Anttila 
2010  Survey Finland 4,121 <12 Parental use of any drug 
(prescribed and OTC) and 
use of any drug in 
children  
Yes 
Log 2013 Retrospectic 
cohort 
(database) 
Norway 97,574 15-16 Repeated opioid and 
analgesic prescriptions in 
mothers and adolescents 
Yes 
Jensen 2014  Survey Denmark 131 6-11 Maternal recurrent 
(monthly) use of 
analgesics and  children 
use of analgesics and/or 
paracetamol (within 3 
months) 
Yes. Not for 
paracetamol 
Bertoldi 2010 Prospectic 
cohort 
(survey) 
Brazil 4,452 11-12 Maternal use of hypnotics 
and/or sedatives (month 
before the survey), and 
use of any drug in 
adolescents in previous 
15 days. 
Yes 
Holdo 2013 Retrospectic 
cohort 
(database) 
Norway 59,325 ≤ 3 Parental use of hypnotics 
(1 year before pregnancy) 
and children chance to 
receive alimemazine (0-3 
years old) 
Yes 
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The studies quantified the association between children and parental use of drugs by 
referring to different drug classes and using different outcomes. The drug classes that were 
investigated in parents were: any drug (two studies), opioid or other OTC analgesics and 
FANS (two studies), and sedatives and/or hypnotics (two studies). The drug classes that 
were investigated in children were: any drug (two studies), opioids and FANS, antibiotics, 
OTC analgesics, , and alimemazine, Table 3. 
Table 3 – Summary of the main outcomes of the studies 
Author Type of study Outcome Statistical method 
mother/parents child 
De Jong Retrospectic 
cohort 
Chronic prescription (at least 
three times per year) 
 
mother 
11.3% 
6.3% 
father 
13.1% 
9.5% 
Recurrent antibiotic 
prescription vs no use of 
antibiotics 
 
-recurrent prescriptions 
- no prescription 
 
-recurrent prescriptions 
- no prescription 
chi squared 
 
 
 
 
 
 
 
 
Hameen-
Anttila 
Cross 
sectional 
(survey) 
Use of any drug (prescribed 
and OTC) 
- Prescribed medicine 
- No prescribed 
medicine 
 
- OTC medicine 
- No OTC medicine 
Total use of medicine (% of 
treated children) 
26.0% 
35.5% p<0.005 
 
 
27.8% 
34.6%  p<0.005 
Multivariable 
logistic regression  
 
 
 
 
Log Retrospectic Repeated prescription  
 
 
Opioids 
No 
Yes 
 
NSAIDs 
No 
Yes 
Repeated prescription 
(prevalence %) 
 
Opioids 
2.4% 
8.4% 
 
NSAIDs 
5.1% 
9.4% 
Multivariable 
logistic regression 
 
 
 
Jensen Cross 
sectional 
(survey) 
Recurrent use of analgesics 
(monthly) 
Analgesic use  
OR 3.00 (1.33-6.73)  
Paracetamol use  
Multivariable 
logistic regression   
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OR 2.54 (0.93-6.92)   
Bertoldi Prospectic 
cohort 
(survey) 
Use of hypnotics and/or 
sedatives (month before the 
survey) 
No use 
 
At least one hypnotic or 
sedative 
 
Both 
Use of any drug (prevalence) 
 
 
29.4% 
 
38.6% 
 
 
41.1% 
Multivariable 
Poisson regression 
 
 
 
Holdo Retrospectic 
cohort 
Past use of hypnotics (1 year 
before pregnancy) 
 
Mother, benzodiazepine 
Father, benzodiazepine  
Mother, hypnotics 
Father, hypnotics 
 
Number of hypnotic 
prescriptions 
None 
1 
2+ 
Chance to receive 
alimemazine 
 
OR 3.0 (1.4-6.7) 
OR 3.1 (1.5-6.5) 
OR 2.2 (1.7-2.9) 
OR 1.6 (1.1-2.2) 
 
 
 
OR = 1 
OR = 1.9 (1.4-2.5) 
OR = 2.5 (1.8-3.4) 
Multivariable 
logistic regression 
 
 
 
 
 
 
Concerning the statistical methods five studies used multivariable regression analyses (four 
studies logistic regression, and one study Poisson regression), while one study used 
univariable analysis methods (chi-squared, odd ratios or relative risks). Three studies 
reported the outcome of interest in both parents, and three studies reported only maternal 
drug prescription or use. An estimation of the main outcome related to the amount of drug 
used or prescribed was made in two studies. Two studies investigated recurrent or chronic 
drug use or prescription. 
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b. The association between child and parents drug prescription or use 
Almost all of the studies retrieved registered a significant association between the children 
drug prescription or use, and that of their parents (mother only, or both parents), Table 2. 
The study by de Jong et al. [15] investigated the association between the prescription of 
any drugs in parents, and antibiotic prescription in children. The authors showed that 
mothers whose children recurrently received antibiotic prescriptions, received at least 
three prescriptions each year of any drug in 11.3% of cases, while mothers whose children 
received no antibiotic until 5 years of age received at least three prescriptions each year in 
6.3% of cases (p<0.001). A similar association was observed in fathers (13.1 vs 9.5%; 
p<0.001). This study did not use any multivariable regression technique, however it was the 
only study that reported the association by drug class separately for mother and father, and 
the association for each drug class. Of the 16 drug classes investigated, three resulted in a 
significant association in both parents: NSAIDs, antacids, drugs for obstructive airway 
diseases. In particular mothers whose children recurrently received antibiotic prescriptions 
had a relative risk of receiving NSAIDs 4.7 (2.6-8.6) times higher than those mothers whose 
children received no antibiotic. The relative risk for father was lower (1.9; 95% CI 1.0-3.5). 
The relative risks for antacids and drugs for obstructive airway diseases were respectively 
2.2 (1.1-4.6) and 2.5 (1.6-3.8) for mothers; and 1.8 (1.2-2.7) and 1.6 (1.0-2.4) for fathers. 
The relative risk was increased only in mothers concerning the prescription of 
antihistamines 3.8 (1.8-8.0), hypnotics and sedatives 3.4 (1.1-10.5), analgesics 3.3 (1.8-6.2), 
anxiolytics 2.4 (1.3-4.6), and antidepressants 1.6 (1.1-2.4). The relative risk was increased 
only in fathers, but not in mothers, concerning cardiovascular drugs 1.6 (1.0-2.5). A 
significant association was not observed for drug classes such as dermatological steroids, 
antipsoriatics, laxatives, drugs for diabetes, antiepileptics, antipsychotics, and 
psychostimulants.  
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Concerning the use or prescription of any drug, only the study from Hameen-Anttila et al. 
[39] investigated this topic at the same time in parents and children by using univariable 
and multivariable analysis. In this study children whose parents currently used at least a 
prescribed medicine were significantly (χ2; p<0.005) more exposed to a medicine 
themselves (35.5%) than children whose parents did not (26.0%). Similar results were 
observed for OTC medicine. The authors also used a logistic regression multivariable 
analysis adjusting for sex, age, health status, symptoms experienced, illnesses diagnosed by 
physician, obtaining that children whose parents currently used at least a prescribed or an 
OTC medicine had a higher chance (respectively OR 1.43; 1.21-1.70, and OR 1.20; 1.01-1.44) 
to receive a prescribed medicine than children whose parents did not. 
Two studies investigated analgesic/NSAIDs use or prescription. Jensen et al investigated 
maternal recurrent (monthly) use of analgesics and children use of analgesics and/or 
paracetamol (within 3 months) [40]. The study design was a cross-sectional survey, and 
they used a multivariable logistic regression to assess the strength of the associations by 
adjusting for a number of covariates such as child pain, mother self-rated health, mother 
chronic pains, mother use of analgesics, mother chronic disease and general background 
information (sex, age, household income, etc..). The chance of the children being treated in 
the last three months with analgesics was 3.0 (1.3–6.7) times higher if the mother used 
monthly an analgesic, while the association was found not significant if the analysis was 
restricted only to paracetamol use (OR 2.5; 95% CI 0.9–6.9). Log et al investigated repeated 
opioid and analgesic prescriptions in mothers and adolescents through a retrospectic 
cohort database study [41]. This study had a large sample size (about 100,000 individuals) 
and used multivariable logistic regression adjusting for mother’s socioeconomic 
characteristics and offspring gender. The percentage of repeated prescription opioid users 
was higher among adolescents whose mother was repeatedly prescribed opioids (8.4 %) 
than among those whose mother was not repeatedly prescribed opioids (2.4 %). A similar 
proportion (9.4% vs 5.1%) was observed for the prescription of NSAIDs. The results of the 
47 
 
multivariable analysis showed an adjusted OR of 3.1 (2.7-3.6) for opioids, and 1.8 (1.7-2.0) 
for NSAIDs. 
Two studies investigated hypnotics use.  
The study of Bertoldi et al. [42] was a survey investigating maternal use of hypnotics and/or 
sedatives in the month before the survey, and use of any drug in their children in the 
previous two weeks. The study used a multivariable Poisson regression analysis by using the 
chance to receive a drug as the outcome measure. The percentage of children receiving a 
drug was 29.4% in children whose mother did not use hypnotics nor sedatives, 38.6% in 
children whose mother used either one hypnotic or sedative, and 41.1% in children whose 
mother used both. The final results of the multivariable model indicated an higher chance 
to receive a drug for children whose mother used either one hypnotic or sedative (OR 1.24; 
95% CI 1.06-1.45), or used both (1.40; 95% CI 1.21-1.62). The model was adjusted for 
variables such as: gender, household assets index, lifestyle, health status, education, 
complication in pregnancy. 
Holdo et al. investigated the association between parental prescription of hypnotics (1 year 
before pregnancy) and children chance to receive alimemazine (0-3 years old) [17]. The 
authors quantified the risk for mother and father separately, and for benzodiazepine and 
non-benzodiazepine hypnotics by using a logistic multivariable regression model. The 
model was adjusted for mothers’ use of antidepressants, mothers’ smoking for both 
genders and mothers’ parity for boys. Children whose mothers used benzodiazepine 
hypnotics were 3.0 (1.4-6.7) times more likely to be prescribed alimemazine than children 
of mothers who did not. Similar findings were found for fathers (OR 3.1; 95% CI 1.5-6.5). 
The same association was investigated for non-benzodiazepine hypnotics and the ORs were 
2.2 (1.7-2.9) for mothers, and 1.6 (1.1-2.2) for fathers. The association increased at 
increasing number of hypnotics prescriptions received: OR 1.9 (1.4-2.5) for male children 
(for females OR 1.7; 95% CI 1.2 to 2.4) whose mother or father received one hypnotic 
prescription (compared to no prescriptions of hypnotic), and OR 2.5 (1.8-3.4) for male 
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children (for females OR 1.7; 95% CI 1.1 to 2.6) whose mother or father received two or 
more prescriptions.  
 
5. Discussion 
The review of the literature showed that the association between offspring and parental 
drug prescription or use is not widely studied, in fact, only six recent study were found. The 
first study concerning this topic appeared in 1980 on the BMJ and was a very simple 
retrospective study, not adjusting for maternal factors or child characteristics [38]. All the 
other studies were published in recent years. The six studies were retrospective cohort or 
surveys and most of them were from the northern Europe.  
The meta-analysis of the data found was not possible because the included studies were 
too heterogeneous in respect to methodology, outcome measures, aims and characteristics 
of the study population. From the qualitative point of view the review showed that there 
was an association between drug use in children and their parents, and also that maternal 
use of hypnotics and sedatives was higher if their child previously used any drug. Besides 
the overall drug use or prescription, other studies investigated antibiotic drug use in 
children as an outcome, finding an association with overall drug use in parents, and another 
study found an increased psychotropic drug use.  
The association between child antibiotic use and parental drug use by classes in the study 
by de Jong et al. showed interesting data, partially confirmed by other studies. There was 
an higher use of antibiotics and antiasthmatics in parents of children receiving antibiotics, 
compared to those who did not receive any antibiotic before 5 years old. This fact could be 
interpreted as an increased susceptibility to infection that is inherited by children, and 
conversely, lead to an increased use of antibiotic. Also anti-asthma prescriptions has been 
related to antibiotic prescriptions [43]. However the study showed that parental use of 
antacids, analgesics, NSAIDs, antidepressant and anxiolitics was associated with child use of 
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antibiotics, while, for example, laxatives, diabetes, antiepileptic drugs and antipsychotics 
were not. These drugs’ indications share a common feature: they are all related to stress 
and anxiety [15]. These data suggest that the association between parental use of different 
drug classes and the use of antibiotics in children may be explained by the fact that these 
families are more prone to use medications and, often, to use them earlier. As suggested by 
other authors, antibiotic prescription is more common in families with a lower socio-
economic profile, greater concerns about infectious diseases, and increased stress of 
fathers [30,31,44-47]. However the scenario is quite complex and this may be true for 
antibiotics, but not for other drugs. For example other authors suggested that OTC drugs 
are administered more to their children by mothers with more education and higher 
household incomes, even if this was not confirmed by the study of Hämeen-Anttila that 
showed no effect of these variables [39,48,49]. 
The higher maternal psychotropic drug use related to the overall child drug use was first 
seen in the study by Howie and colleagues in 1980. This study and the one by de Jong et al. 
share the fact that they did not adjust for socioeconomic and other potentially relevant 
parental variables because such data were not available. The studies from Hämeen-Anttila 
and Bertoldi and colleagues adjusted for parental background information and, while they 
were different in terms of design and aims, both studies showed that the chance to receive 
any drug or hypnotics was increased in mothers of children receiving more drug 
prescriptions. Compared to studies that did not adjust for family background information 
these two studies obtained much less strong results, yet still significant, in terms of odds 
ratios.  
The paternal information was reported only in two out of seven studies. Usually the 
association with paternal drug exposure was less convincing than the association observed 
in mothers. This may be because mothers are usually more involved with the care of the 
children, and may have more opportunity to discuss prescription for their children. 
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Besides the different aims and methodologies of the included studies, an important 
limitation was the hugely variable sample size among them. The lack of statistical power 
was an important limitation of some of the studies, and it hindered the possibility to show 
differences and associations in the chance of drug exposure in subgroups. It is the case of 
the study by de Jong at al. In fact the number of individuals receiving different drug classes 
ranged from 1 to 76, leading to very large confidence intervals. This fact prevented to reach 
the significance for some of the drug classes analysed. Also other studies had few overall 
individuals included, like the study by Jensen and colleagues. In particular this study was 
underpowered to show a significant difference in the child chance of being treated with 
paracetamol when the mother used monthly an analgesic, even if the effect size was quite 
large (OR=2.5). Another limitation of these studies is the lack of data concerning the 
physician that is prescribing drugs, which is absent in all the studies retrieved. Some 
physicians prescribe medication more easily than others, and their influence is important in 
determining drug prescription in mothers and their children, especially if the physician is 
the same, which may be often the case in many countries. 
 
6. Conclusions 
The different outcome measures, methodology, and information available used in the 
studies retrieved lead to very difficult comparison among the results, and, in turn, to 
difficult conclusions. There is indeed evidence of an association between maternal drug use 
or prescription in general and children drug use of prescription. The strength of association 
is higher for mothers drug use more than it is for fathers, and it is higher for prescription 
drugs other than OTC drugs, even if only a minority of studies looked at these outcomes. 
Overall the studies looked at different endpoints and, thus, the association found for many 
drug classes has been investigated only by one or a few studies. From some of the studies 
the hypothesis of an increased susceptibility to infection that could be inherited by 
children, and conversely, lead to an increased use of antibiotic seems possible. However 
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there are also indication that mainly the kind of drugs that are related to stress and anxiety 
are related to drug use in the offspring, and this could means that some families are more 
prone to use medications and, often, to use them earlier.  
A study on this topic was not possible to conduct in this PhD thesis because a deterministic 
link between mother and child was not possible with these databases. There is a need for 
more studies looking at the association between child and parental drug use or prescription 
since there is not a standardised methodology to conduct such studies, there are a number 
of possible endpoints of interests, and the sample size is often non-sufficiently large. Finally 
there is a need for more studies that includes information about cultural, behavioural and 
socio-economic backgrounds, since the literature shows that these variables may be among 
the most important factors influencing drug use in the family. 
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V. Determinants of drug prescribing: drug utilisation studies in 
paediatrics 
 
 
 
 
 
 
 
A. Antibiotic and anti-asthmatic drug prescriptions in Italy: geographic patterns 
and socio-economic determinants at the district level 
1. Introduction 
The prevalence of drug prescription in Italian children is among the highest in Europe and 
the most frequently prescribed classes are antibiotics and anti-asthmatics [50]. 
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As already described, large qualitative and quantitative differences in antibiotic exposure 
between countries have been found [4]. Wide differences have also been observed in 
children’s exposure to anti-asthmatics between different countries: prevalence (percentage 
of children receiving at least one prescription in a year) ranges from 6.2% in Norway to 19% 
in Italy [5]. ß2-mimetics and inhaled steroids are the most frequently prescribed anti-
asthmatics in Italy and their use is, respectively, threefold and fourfold higher than in UK 
and in the Netherlands [9]. In Italy the prevalence of anti-asthmatic drugs is much higher 
than prevalence of disease, indicating that anti-asthmatics are over-prescribed [9,23]. 
In Italy the prevalence rate for all drugs prescribed to children and adolescents is 57.3% in 
the North, while it is 68.3% in the South [50]. The prescription profile of antibiotics has 
been extensively described at the regional level. The highest prevalence rate is found in 
southern regions and differences at the LHU level range from 35.6% to 68.5% [6]. Under use 
of recommended drugs, such as amoxicillin, is an issue, especially in the southern part of 
the country, with an excessive exposure to second choice treatment (i.e. oral and 
parenteral cephalosporins) [6]. Notable differences have been demonstrated also within 
regions, as is the case in the Lombardy Region, where the prevalence rate for all drugs 
ranged from 38.4% in Milano’s LHU to 54.8% in Brescia’s LHU in 2006 [20]. The anti-
asthmatic prescription patterns within Italy have not been investigated in depth, however, 
it is known that beclometasone (which is often related to inappropriate or unlicensed use in 
Italian children) is the most used anti-asthmatic drug and is most used in the South [8,51]. 
In this context a comparison between the two most used drug classes (that are 
characterised by high inappropriateness of use in Italy) at a district level was made. Three 
prominent regions were included: Lombardy, Lazio, and Puglia. The aim of this study was to 
evaluate the antibiotic and anti-asthmatic drug prevalence rate at the district level as well 
as the influence of territorial setting, including a few socio-economic determinants, on an 
Italian child and adolescent outpatient population. 
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2. Methods 
a. Data source 
Data sources were regional databases routinely updated for administrative and 
reimbursement reasons. The databases stored all community prescriptions reimbursed by 
the NHS. The study population was composed of 3,301,096 children and adolescents <18 
years old (32.5% of the population <18 years old), living in three large Italian regions: 
Lombardy (1,616,268 resident children), Lazio (926,015) and Puglia (758,813), from North 
to South. The observation period was from 1 January to 31 December 2008 for all regions. 
Overall, 193 healthcare districts (45 in Puglia, 55 in Lazio and 95 in Lombardy Region), 
participated in the study. The cities of Rome and Milan were considered as a whole and not 
as “composed by districts”, because data on such aggregation level were not available. Two 
of 95 districts from Lombardy Region were excluded from the analyses because their 
paediatric population size was under the first percentile of the distribution of the 
population by district. The average number of resident children/adolescents in each district 
was 16,932 (ranging from 16,237 in Lazio to 17,375 in Lombardy Region). 
All drugs were classified according to the ATC system (Anatomical Therapeutic Chemical 
classification system). In this study antibiotics were considered as every drug belonging to 
the J01 sub-group and  anti-asthmatic as to every drug belonging to the R03 sub-group. 
b. Measures 
In order to describe the prescription profile the prevalence rate for antibiotics and anti-
asthmatics was calculated at the district level. The prevalence rate was the number of 
individuals who received at least one prescription in one year, divided by the number of 
children/adolescents. 
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The all-cause hospitalisation rate and hospitalisation rate for asthma as primary or 
secondary diagnosis were calculated by district, expressed as the number of patients 
admitted to the hospital at least once in one year (ordinary admissions) divided by 1000 
resident children/adolescents. Data were retrieved from hospital discharge records, which 
include information on primary diagnoses and up to five co-existing conditions such as 
secondary diagnoses, procedures performed, date of admission, discharge, and in-hospital 
death. Asthma diagnoses were classified according to ICD9 (International Statistical 
Classification of Diseases and Related Health Problems) code 493. The number of FPs per 
1000 resident children under 12 years old was calculated by district.  
Demographic distribution among the three age strata (0-5, 6-11 and 12-17 years old) was 
heterogeneous across the districts, possibly influencing prevalence. In order to adjust 
prevalence by age a standardisation method was applied. A logistic regression analysis, 
using the Lombardy Region database to evaluate the association between drug prescription 
and age, was performed [20]. The adjusted odds ratios (see the previous reference for 
details) were used as “weight” in the standardisation and were calculated for three age-
strata: ≤5years old (OR=1.77), 6 to 11 years old (OR=1), and 12 to 17 years old (OR=0.70). 
By using the age-specific weight and prevalence, the age-corrected prevalence for each 
district for antibiotic and anti-asthmatic drugs were obtained [52,53]. All data analyses 
were performed using the age-corrected prevalence. 
An indirect standardisation method was also applied to prevalence for antibiotics and anti-
asthmatics in all districts in order to calculate the standardised prevalence ratio (SPR). The 
indirect standardisation uses age-specific prevalence from the overall population to derive 
the numbers of expected cases in the region’s population (i.e. district). SPR indicates 
whether the prevalence rate observed at a district level is significantly higher or lower than 
what wouyld have been observed in the standard population. Confidence intervals were 
calculated with a shortcut method [54]. Districts with a SPR that is significantly lower than 1 
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will be referred to as “lower than expected” and those having a SPR significantly higher 
than one as “higher than expected”.  
SPR= Tobs/ Texp= Tobs/[Sum age groups (PasNas)] 
SPR = Standardised prevalence ratio 
Tobs = number of treated children (district). 
Texp= number of expected treated children (district) 
Pas = age-specific prevalence rate (standard population). 
Nas = number of people in the age-specific group (district). 
 
A choropleth map of SPR for antibiotics and anti-asthmatics was elaborated at the district 
level [12]. The map was created using the software Arcmap 10.1. 
The non-parametric Spearman test was used to evaluate the correlation between antibiotic 
and anti-asthmatic prevalence and some determinants including: average annual income 
per inhabitant, latitude, number of FPs per 1000 resident children, and hospitalisation rate 
for all causes and for asthma. 
The ANOVA test and the Bonferroni post-hoc test were used to compare the prevalence 
rate by districts in the three regions. The chance of receiving an antibiotic or anti-asthmatic 
prescription for children resident in districts with a lower average annual income per 
inhabitants (lowest quintile) versus a higher average annual income (highest quintile) was 
calculated. The coefficient of variation (CV) was used to assess the variability of district 
prevalence among LHUs. 
3. Results 
a. Regional prescription profile 
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During 2008, 1,861,425 children and adolescents (56.4% of the study population) received 
at least one drug prescription. Antibiotic prevalence rate was, on average, 47.9%, ranging 
from 44.1% in the Lombardy Region to 57.5% in the Puglia Region. 
Table 4 – Average district prevalence (%) and anova test on the prevalence rates grouped 
by region 
 antibiotic drug prevalence (%) anti-asthmatic drug prevalence (%) 
range mean ± sd range mean ± sd 
Lombardy (95) 34.0-55.1                   44.1 ± 4.1 11.7-26.0                        17.8 ± 3.3 
Lazio (55) 35.6-66.7                   49.8 ± 6.7 17.3-32.4                        25.1 ± 3.6 
Puglia (45) 48.0-67.9                   57.5 ± 4.9 17.4-35.5                        26.5 ± 4.6 
ANOVA test F= 105.26                   p< 0.0001 F=112.30                         p< 0.0001 
 
Anti-asthmatic prevalence was, on average, 21.4%, ranging from 16.9% in Lombardy to 
27.0% in Puglia. The male/female odds ratio for prevalence for antibiotics was, on average, 
1.05 (95% CI 1.05-1.06), with no significant differences between regions, while for anti-
asthmatics it was 1.21 (1.20-1.21) with a slightly higher ratio in Lombardy (1.24; CI 1.23-
1.25) compared to Lazio and Puglia (1.18; CI 1.17-1.19). 
 
b. Prescription profile at the district level 
The age-corrected prevalence for all drugs ranged from 41.0% to 74.7%, from 34.0% to 
67.9% for antibiotics and from 11.7% to 35.6% for anti-asthmatics. The age-corrected and 
crude prevalence differed significantly only in a few districts that had a small population 
size. The ANOVA and Bonferroni tests showed a significant difference in the prevalence of 
antibiotic and anti-asthmatic drugs in districts across the three regions (Table 4; p<0.001), 
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with the exception of anti-asthmatic prevalence in Lazio and Puglia (p=0.19). Prevalence 
was much lower in Lombardy Region compared to the other two regions, considering both 
antibiotics and antiasthmatics. 
SPR ranged from 0.70 to 1.44 for antibiotic drugs and from 0.54 to 1.72 for anti-asthmatic 
drugs, Figure 3. In Lombardy 69% of the districts (66/93) had a SPR lower than expected for 
both anti-asthmatics and antibiotics. On the contrary, in Puglia, no district had a SPR lower 
than expected and in 82% of them (37/45) the SPR was higher than expected. Only a few 
districts in Puglia had an antibiotic and antiasthmatic prevalence comparable to those in 
Lombardy Region. Large differences were observed in the variability of district prevalence 
within each LHU: CV ranged from 0.01 to 0.15 for antibiotics and from 0.03 to 0.22 for anti-
asthmatics. 
The median average annual income per inhabitant was 7,187 € (interquartile range, IQR = 
6,440-8,262 €) in the high-prevalence districts (districts having both antibiotic and anti-
asthmatic drug prevalence over the mean plus one SD), while it was 15,360 € (IQR = 13,358-
16,837 €) in the low-prevalence districts (prevalence under the mean minus one SD). 
 
 
 
Figure 3 - Choropleth map of the standardised prevalence ratio (SPR) at the district level 
for antibiotics and anti-asthmatics. The SPR indicates whether the prevalence observed in 
each district is significantly higher (SPR>1) or lower (SPR<1) than expected by using a 
standard population as a reference (the overall study population). 
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c. Determinants 
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The Spearman test scored a significant positive correlation between antibiotic and anti-
asthmatic prevalence at the district level (rS = 0.77; p< 0.001). The within-region correlation 
was significant, but less strong, especially in Lombardy (rS = 0.57; p< 0.001) and Puglia (rS = 
0.50; p< 0.001). 
There was a significant inverse correlation between average annual income per resident 
and both the prevalence of antibiotics (rS = -0.77 p<0.001) and anti-asthmatics (rS = -0.73 
p<0.001). Children resident in districts in the lowest quintile of annual income per resident 
had a higher chance (highest vs lowest quintile) of receiving an antibiotic (OR 1.75, 95% CI 
1.74-1.77) or anti-asthmatic drug (OR 1.56, 95% CI 1.55-1.57), Table 5. 
The correlations between prevalence of antibiotic and anti-asthmatic drugs toward other 
determinants are reported in Table 6. Latitude was inversely correlated with antibiotic and 
antiasthmatic prevalence. There was not a correlation between hospitalisation for asthma 
and antiasthmatics prevalence. The number of FPs per 1000 inhabitants was not relevantly 
correlated with prevalence. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 – Analysis of the correlation between antibiotic (J01) and anti-asthmatic (R03) 
prevalence versus average annual income per resident at the district level, numbers in 
brackets are confidence intervals. 
prevalence average annual income at the area level 
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overall lowest vs highest quintile 
rS OR 
Lombardy 
  antibiotics -0.27 1.23 (1.22-1.24) 
anti-asthmatics -0.46 1.25 (1.24-1.27) 
Lazio 
  antibiotics -0.55 1.31 (1.30-1.33) 
anti-asthmatics -0.38 1.16 (1.15-1.18) 
Puglia 
  antibiotics -0.34 1.29 (1.27-1.30) 
anti-asthmatics -0.02* 1.03 (1.02-1.05) 
Total 
  antibiotics -0.77 1.75 (1.74-1.77) 
anti-asthmatics -0.73 1.56 (1.55-1.57) 
*non-significant p-value (>0.05) 
 
Table 6 – Correlation between prevalence of antibiotic and anti-asthmatic drugs vs other 
determinants at the district level 
prevalence vs: rS p-value 
Latitude (South to North)   
antibiotics -0.71 <0.001 
anti-asthmatics -0.72 <0.001 
Hospital admission rate   
antibiotics* 0.33 <0.001 
anti-asthmatics° 0.03 0.65 
FPs per 1000 inhabitants   
antibiotics -0.19 0.01 
anti-asthmatics -0.02 0.80 
 
*all cause hospitalisation rate 
° hospitalisation rate for asthma 
 
 
4. Discussion 
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This is the first Italian study evaluating antibiotic and anti-asthmatic prescriptions at the 
district level in three large Italian regions. The result concerning antibiotics was similar to 
what was observed, at the LHU level, in a previous study [6], although prevalence rate 
ranges at the district level were wider than those found in the previous study (e.g. in 
Lombardy the range was 34.0-55.1% at the district level, while it was 36.3-50.6% at the LHU 
level). In particular, this study underlines the fact that, even in settings characterised by low 
prevalence (i.e. Lombardy), there are districts with a higher prevalence than expected and 
that variability is often very high even among districts within the same LHU. The use of anti-
asthmatics was found to be higher than in a previous study in children (same age group) in 
the North [23], while it was similar to what was observed in another Italian paediatric 
population [55].  
The current study shows that the use of anti-asthmatics, as well as antibiotics, is higher in 
the South and that there is a correlation between anti-asthmatic and antibiotic use at the 
district level. In particular, the SPR (for both antibiotics and anti-asthmatics) increases from 
North to South. Another study already showed that Italian children living in the South have 
a greater chance of receiving a prescription of any drug compared to their counterparts 
living in the rest of the country [8]. Since antibiotics and anti-asthmatics are the most 
commonly prescribed drugs in Italy this finding is in part expected and may mean that the 
geographical differences observed may not be linked to a particular class of drugs, but to 
other, independent factors.  
The association between asthma and antibiotic use in children has already been shown in 
the literature [56-58]. The relationship between anti-asthmatic and antibiotics prescription, 
however, is a quite different phenomenon. In fact, particularly in Italy, anti-asthmatic drug 
consumption in an outpatient setting is not a good disease indicator, since the 
inappropriate use of this drug class is very high [9]. The unreliability of anti-asthmatic 
consumption as a disease indicator in this setting is evident if one looks at its association 
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with hospitalisations for asthma: they are unrelated. For this reason the correlation among 
the use of these two drug classes probably is thought to be due to a generalised 
inappropriate use of drugs and not to the asthma-antibiotic use link. 
Concerning income, children living in low income districts have a higher chance of receiving 
a prescription of an antibiotic or an anti-asthmatic. This trend persists within regions/areas 
characterised by different prescribing volumes. The finding that there is a twofold absolute 
difference in the average annual income per inhabitant between the high and the low 
prevalence districts is striking. Similar findings have been recently found in Germany [59] 
and in Switzerland as well [60]. In these countries, as in Italy, the cost of antibiotic and anti-
asthmatic drugs is, at least partially, reimbursed. In these cases, given the methodology 
used, the confounding role of out of pocket drug use cannot be excluded [8].  
Concerning latitude, the prevalence is higher in southern Italy, but this is not true in 
Germany, where antibiotic use is higher near the upper-western border and the far north. 
The inverse correlation between latitude and antibiotic/anti-asthmatic drug prescription is 
valid in Italy, where the North-South socio-economic polarisation is well known, but not 
necessarily in other countries. Another study on antibiotic prescriptions found that in 
Lombardy there is a West-East geographic trend more than a North-South one [12]. In this 
study, latitude and average annual income were both related to prevalence of antibiotics 
and anti-asthmatics (the two indicators are co-llinear) but the hypothesis is that income is a 
more relevant variable, because, when looking at prescriptions within regions of different 
income levels, a similar, even if weaker, association persists.  
A plethora of other factors possibly associated with drug prescription to children (mainly 
antibiotics) have been considered in a number of international and Italian studies 
[13,14,61-65]. Education and income level are factors known to indirectly affect individual 
health. Various studies agree in demonstrating that poor and less educated people have 
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inadequate access both to primary prevention and to early diagnosis [66]. These facts could 
also reflect a lower quality of children’s healthcare. A lower educational level could also 
affect the understanding of the therapy’s importance and, indirectly, how much the 
prescriber perceives the parental expectation of a prescription, the latter of which is a 
known factor influencing the physician’s decision [13]. It has been demonstrated that 
parents of children receiving many antibiotics use more medicines themselves [15]. These 
data reinforce the hypothesis that area income deprivation is only a proxy of other linked 
deprivations, which are probably more relevant or more directly affect the amount of 
prescriptions in children. In particular educational deprivation, which is very often related 
to income deprivation [67], may have, at least in part, a causal role in the amount of 
medicines prescribed to children. The role of the prescriber is also particularly important: in 
Lombardy, in the highest prevalence areas, a higher number of FPs classified as high 
prescribers was found [12].  
Ultimately, the current study shows that prescribing distribution at a micro-level is 
associated with socio-economic inequalities, even if the Italian NHS fully reimburses 
antibiotics and anti-asthmatics. A recent study in the same setting (Lombardy Region) 
showed that a local educational intervention on FPs was able to improve the prescription 
profile [22]. If education (of families and physicians) is one of the most important factors 
affecting prescribing, policy makers should take into account the differences highlighted in 
order to plan educational interventions to reduce prescription and implement a more 
rational drug use. 
Finally, as a methodological issue, this study underlines the importance of the evaluation of 
epidemiological outcomes also in small census areas. The prescription profile of a region 
cannot be representative of the national pattern. On the other hand, the profiles observed 
at the national and regional levels are not applicable at the district level. From this point of 
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view, the local context influences drug prescriptions and its role should be investigated as 
part of the monitoring of drug utilisation. 
a. Strengths and weaknesses 
This study is able to provide more robust data on the association between income and 
prescription of reimbursed drugs to children by including an analysis of data at the district 
level. The entire child/adolescent population of three regions, representative of different 
geographical and economic settings, was included, avoiding selection bias (e.g. different 
social or educational backgrounds). The prevalence by age, which is the most important 
factor associated with a higher drug prescription in children, was standardised in this study. 
However, some limitations must be considered. 
Since reimbursement data were analysed, it was not possible to ascertain adherence to 
prescribed treatments. This is a limitation because other studies on adult patients reported 
low adherence rates in primary care [68], even if in paediatric patients the phenomenon 
may be limited. The use of aggregated data precluded the application of more appropriate 
statistical methods such as logistic regression analysis. Furthermore, data on out of pocket 
drug use was not available for antibiotics and anti-asthmatics (although they are fully 
reimbursed). Out of pocket drug use could potentially bias the relationship between higher 
anti-asthmatic and antibiotic drug consumption and lower income as described elsewhere 
[8]. However, it is likely that the phenomenon is limited for reimbursed drugs. 
5. Conclusions 
The current study highlights anti-asthmatic and antibiotic prescription differences at the 
district level showing wide local differences and specificities that were not demonstrable in 
other studies. Anti-asthmatic and antibiotic drug prescribing are related and their use is 
higher in the South of Italy. The data confirm the presence of an inverse association 
between annual income and the prevalence of antibiotic and anti-asthmatic drugs also at 
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the district level. Local socio-economic inequities can concur in prescribing distribution and 
must be considered when planning educational interventions to reduce prescription and 
increase rational drug use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. A multiregional study about psychotropic medicine prescriptions 
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1. Introduction 
Paediatric psychopharmacology has developed rapidly over the last few decades. Large 
randomised clinical trials focused on the treatment of a spectrum of psychiatric illnesses - 
such as ADHD [69], bipolar mania[70], behavioural problems associated with autism [71], 
and depressive [72] and anxiety disorders [73] – have been published, and the emphasis on 
pharmacological treatments has grown considerably. 
As an increasing number of young patients began to receive psychotropic drugs, attention 
to the safety profile of such drugs in paediatric patients increased. In 2004 the US Food and 
Drug Administration (FDA) issued a safety warning – the so called “black box” warning - 
about the twofold higher risk of suicidal behaviour in adolescents receiving antidepressants 
[74]. Other important safety issues emerged, such as the increasing awareness of adverse 
metabolic effects of second-generation antipsychotic medicines [75], and the abusive 
potential of psychostimulants [76,77]. Since then, paediatric psychopharmacology has 
become an increasingly relevant component of youths’ healthcare, and several drug 
utilization studies have been performed with the aim to evaluate psychotropic drug use and 
prescribing.  
Large variations were found in the psychotropic prevalence among youths worldwide [26, 
78-85]. Prevalence in Italy is lower (about 3‰)[78] than in Europe and in the US (up to over 
6%)[26,79]. The same general trend is noticeable in the different classes of psychotropic 
medications. For example, the prevalence of antidepressants ranges from over 2% in US 
[79] and 1.7% in Denmark [80] to 2.4‰ in Italy [78]. Concerning drugs used for ADHD the 
prevalence  ranges from 2 to 4% in the US and Iceland, and from 1 to 2% in Australia, 
Canada, Israel, and the Netherlands [81-85]. A similar trend was observed for 
antipsychotics: they are rarely prescribed in Italy (0.7 ‰) [78], while their prevalence is 
about 1% in the US [79]. 
Large differences between countries are also present in terms of policy and resources for 
care and services for paediatric mental health. Only 1 in every 4 cases has access to services 
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in high income countries [86], while in low and middle income countries the rate can be 20 
times lower [87]. These factors, together with many others, contribute to the wide gap 
observed in treatments worldwide, where in some countries (especially in Europe) children 
are more likely to be pharmacologically undertreated with respect to their clinical needs, 
while in the US, where such drugs are overprescribed, the opposite is true [88,89]. There is 
also evidence that the chance of receiving an antidepressant may vary within the same 
country [90], where policy and organization of services are expected to be more 
homogenous. In this context it is essential to monitor psychotropic drug use in youths.  
Data on paediatric psychotropic medication prescription and use in Italy are sparse and not 
updated [27,78,91]. In fact, the only two studies published in the last five years reported 
data of a single region or LHU [27,91], and the only study representative of the Italian 
paediatric population reported 2004 data [78]. Data concerning the psychotropic drug 
prescription in the general population showed that there are differences in the amount of 
prescriptions filled at the regional level, and this could reflect differences in the prevalence 
of psychiatric disorders, and also in the access to psychiatric services [92].  Since a 
continuous monitoring and surveillance on paediatric psychotropic drug prescription is 
essential, we analysed the prescription of psychotropic drugs from 2006 to 2011. In order 
to assess for the first time differences among regions, we included seven Italian regions 
belonging to different geographical areas, providing a large - half of the paediatric 
population - and representative sample of the Italian child and adolescent population. Since 
there could be differences in the epidemiology of psychiatric disorders, we also collected 
the hospital admission rates at the regional level as a proxy of severe psychiatric illness in 
order to compare them to the prevalence of psychotropic drugs. 
 
 
2. Methods 
a. Data source 
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Data sources were regional databases routinely updated for administrative and 
reimbursement reasons. The databases store all outpatient (i.e. outside the hospital) 
prescriptions reimbursed by the NHS.  
In November 2013, Italian researchers who were part of the ENCePP® (European Network 
of Centres for Pharmacoepidemiology and Pharmacovigilance) network [93] were asked to 
participate in the study.  
Seven of the eleven regions contacted participated in the study: Veneto, Lombardy, Friuli 
Venezia Giulia, Emilia Romagna, Abruzzo, Lazio and Puglia (69 LHUs). The centres involved 
have a long-standing experience in pharmacoepidemiological studies, and in the analysis of 
health administrative databases. Each researcher provided the prescription data concerning 
psychotropic drug prescriptions for the paediatric outpatient population (<18 years old) in 
his own region, through an agreement with the Regional Ministry of Health. For the Veneto 
Region data were provided for 15/22 LHUs (597,596 children and adolescents, 77% of the 
regional population), which were those included in the CINECA consortium, a National 
Interuniversity Consortium constituted with the purpose of providing a friendly and 
efficient database that collects and monitors the GPs’ prescriptions [78]. All regions 
provided data from 2006 to 2011. For the Abruzzo Region, data for years 2010-2011 were 
provided. 
The study population in 2011 was composed of 5,019,564 youths less than 18 years of age 
living in the regions participating, representing 50.2% of the Italian population of this age. 
The regions were representative of different geographic areas: North of Italy (Friuli Venezia 
Giulia, Lombardy, Emilia Romagna and Veneto, 71.2% or the North population), Centre 
(Lazio, 49.9%), and South (Puglia and Abruzzo, 36.5%). The seven regions had different 
economic backgrounds. In particular the mean annual income per resident in 2011 in Italy 
was 12,159 €, and ranged from 8,382€ (Puglia) to 15,502€ (Lombardy), source: Italian 
ministry of Economy and Financial Affairs. 
Aggregated, anonymous data were provided so ethical approval was not required.  
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Psychotropic drugs were defined according to the World Health Organization categories 
and comprised the following subgroups of the Anatomic Therapeutic Chemical (ATC) 
classification system: antipsychotics (N05A), antidepressants (N06A) and centrally acting 
sympathomimetics (ADHD medications, N06BA). Anticonvulsants (N03 subgroup) were 
excluded because in children they are mainly used to treat epilepsy, while anxiolytics, 
sedatives, and hypnotics were excluded because they are not reimbursed by the Italian 
NHS, and thus not retrieved in the database, as stated above. 
Data concerning hospital admissions for psychiatric diagnoses were also collected at the 
regional level as a proxy of severe psychiatric illness in order to compare them to the 
prevalence of psychotropic drugs. To this purpose, the following ICD-9 codes were 
considered: 290 to 319. 
 
b. Data analysis 
For 2011 the following outcome measures were calculated by age and gender for the 
overall sample and for each region: 
- Prevalence of current users, defined as the number of individuals who received at 
least one psychotropic drug prescription per 1,000 youths; 
- Incidence of new users, defined as the number of people who received a 
psychotropic drug prescription for the first time (did not receive it during the 
previous year) per 1,000 youths; 
- prescription rate, defined as the number of prescriptions per youth treated with at 
least one psychotropic drug in one year; 
- hospital admission rate, defined as the number of resident youths admitted to 
hospital due to any psychiatric illness at least once in one year per 1,000 youths.  
 
For the 10 most prescribed psychotropic drugs in 2011 the prevalence was calculated for 
the following age strata: 0-5, 6-11, and 12-17 years old. Furthermore, the percentage of 
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treated youths (number of children and adolescents who received at least one prescription 
of a certain drug, divided by the number of children that received any psychotropic drug 
prescription during one year) was calculated for each active substance. 
For 2011 the main indicators (not stratified by age and gender) at the LHU level were 
retrieved. A choropleth map of prevalence at the LHU level was created using the software 
Arcmap version 10.1. The prevalence values were categorised into three classes calculated 
on the basis of the mean±1 sd.  
The temporal utilization trend of psychotropic drugs in youths in the period 2006–2011 was 
analysed. Prevalence, incidence, prescription, and hospital admission rates were calculated 
for all psychotropic drugs and for antipsychotics, antidepressants, and ADHD medications 
separately. The 5-year cumulative incidence of psychotropic medications was calculated for 
the 2007-2011 period.  
The coefficient of variation (CV) was used to assess the variability in prevalence reported by 
LHUs among regions. The Welch’s ANOVA and the Tukey post-hoc tests were used to 
compare the prevalence reported by LHUs in the included regions. The chi-squared for 
linear trend (χ2 trend) test was used to investigate the presence of a trend in the  
prevalence of psychotropic, antidepressant, antipsychotic and ADHD medications over the 
years in the whole population studied and in each region. The area under the prevalence–
time curve (AUC) was calculated according to the linear trapezoidal rule for the intervals: 0-
5, 6-11, 12-17 years in respect to gender. The Pearson test was used to investigate the 
correlation between prevalence and prescription, hospital admission rates, latitude, 
longitude and average annual income at the LHU level. A p-value <0.05 was considered 
statistically significant. Statistical analysis was performed using SAS software, version 9.2 
(SAS, Cary, NC, USA). 
3. Results 
a. Overall study population 
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During 2011, 8,834 youths received at least one psychotropic drug prescription. The 
prevalence was 1.76‰ (95% CI 1.72-1.80), Table 7.  
 
Table 7 - Number of youths 0–17 years old, number of LHUs, average prevalence of 
prescription, prescription and hospital admission rate percentage by region, ordered by 
decreasing latitude from top to bottom (year 2011) 
Regions 
Population 
(n) 
LHUs 
(n) 
Prevalence Hospital 
admission rate 
(‰) 95% CI Range by 
LHU 
Male/ 
female 
ratio 
(‰) 95% CI 
FVG* 184,553 6 2.17 1.96-2.39 1.87-2.51 1.35 3.82 3.54-4.11 
Veneto 597,596 15 1.57 1.47-1.67 1.07-2.25 1.36 3.40 3.25-3.55 
Lombardy 1,688,543 15 1.56 1.50-1.62 1.09-2.78 1.26 1.12 1.07-1.17 
E.Romagna 695,043 11 1.97 1.87-2.08 0.97-2.30 0.97 0.66 0.60-0.73 
Abruzzo 205,774 4 1.88 1.69-2.06 1.39-2.68 1.50 0.89 0.77-1.02 
Lazio 925,339 12 1.96 1.87-2.05 1.43-2.22 1.28 0.60 0.55-0.65 
Puglia 722,716 6 1.78 1.68-1.87 1.54-2.11 1.53 1.75 1.65-1.85 
Total 5,019,564 69 1.76 1.72-1.80 0.97-2.78 1.27 1.41 1.38-1.45 
*Friuli Venezia Giulia 
 
Antidepressants were prescribed to 5,100 youths (1.02‰; 95% CI 0.99-1.04), antipsychotics 
to 3,512 youths (0.70‰; 95% CI 0.68-0.72), and ADHD medications to 976 youths (0.19‰; 
95% CI 0.18-0.21). The mean number of prescriptions per treated youth was 4.4 for 
psychotropic drugs, and ranged from 3.2 for antidepressants to 6.0 for ADHD medications.  
The psychotropic drug prevalence increased by increasing age following an exponential 
trend, both in males and females, with negligible exposure in the first year of life and 7.5‰ 
exposed at 17 years old, Figure 4.  
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Figure 4 – Prevalence (per 1,000) by age and gender (Male:  Female:   ) of overall 
psychotropic drugs (A), antidepressants (B), antipsychotics (C), and ADHD medications 
(D). 
 
 
While antidepressants were the most prescribed psychotropic drug class in the overall 
population and in females (AUCN06A/all psychotropic drugs = 0.76), antipsychotics were the most 
prescribed psychotropic drugs in males (AUCN05A/all psychotropic drugs = 0.48). The prevalence of 
psychotropic medications was similar for males and females  up to 5 years old, was higher 
in males in the 5-15 year range, and was higher in females afterward. Males were more 
exposed to psychotropic drugs than females (AUC0–17 male/female = 1.23), particularly in 
the school age (AUC6–11 male/female= 2.52). The disproportion was particularly evident for 
ADHD medications (AUC0–17 male/female = 5.06) and antipsychotics (AUC0–17 male/female = 
2.16). Females were more exposed to antidepressants than males (AUC0–17 male/female = 
0.74). With antidepressants, the trend by gender and age was very similar that of 
psychotropic drugs, and began to increase in pre-adolescents, with females receiving more 
antidepressants than boys after 15 years of age (fig.4). The prevalence of antipsychotics 
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began to increase in school-aged children, with males being more exposed than females at 
any age. For ADHD medications the highest prevalence was in nine year old children, 
particularly males, while the female prevalence was negligible at any age (fig.4). 
The incidence of psychotropic drug prescriptions was 1.03‰ (95% CI 1.00-1.06), with no 
significant differences between males and females (AUC0–17 male/female = 1.02; 95% CI 
1.00-1.05). The incidence of antidepressants was 0.69‰ (95% CI 0.67-0.72), while that of 
antipsychotics was 0.32‰ (95% CI 0.31-0.34), and that of ADHD medications 0.08‰ (95% 
CI 0.07-0.09). The 5-year cumulative incidence of psychotropic medications in the 2007-
2011 period was 4.29‰, with a total of 26,142 incident cases. 
The hospital admission rate was 1.41‰ (95% CI 1.38-1.45). In 2011, a total of 20 different 
drugs were among the list of the ten most prescribed psychotropic drugs in the 
participating regions, Table 8. The most prescribed psychotropic drug was risperidone 
(20.6% of children treated with psychotropic drugs), followed by sertraline (18,0%), and 
methylphenidate (7.1%). 
 
 
 
 
 
 
 
 
 
 
Table 8 - The prevalence per 10.000 resident youths of the ten most prescribed 
psychotropic drugs in 2011 by age group. Drugs not approved for use in each age group 
are reported in italic. 
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0-5 6-11 12-17 
Drug * Drug * Drug * 
Trazodone 0.310 Risperidone 3.31 Sertraline 8.77 
Risperidone 0.240 Methylphenidate 2.12 Risperidone 7.70 
Escitalopram 0.181 Sertraline 1.01 Fluoxetine 3.37 
Citalopram 0.158 Atomoxetine 0.63 Paroxetine 3.30 
Sertraline 0.135 Periciazine 0.36 Escitalopram 2.26 
Venlafaxine 0.111 Pimozide 0.36 Aripiprazole 2.24 
Duloxetine 0.100 Amitriptiline 0.34 Citalopram 1.78 
Paroxetine 0.082 Aripiprazole 0.23 Methylphenidate 1.57 
Periciazine 0.053 Haloperidol 0.20 Olanzapine 1.17 
Quetiapine 0.041 Chlorpromazine 0.18 Atomoxetine 0.66 
* x 10,000 
 
b. Regional profile 
During 2011, the prevalence of psychotropic drugs ranged from 1.56‰ (95% CI 1.50-1.62) 
in the Lombardy Region to 2.17‰ (95% CI 1.96-2.39) in the Friuli Venezia Giulia Region, 
Table 7. At the LHU level the prevalence ranged from 0.97 to 2.78‰, Table 7, Figure 5. The 
CV of regional prevalence ranged from 0.13 in the Friuli Venezia Giulia Region to 0.29 in the 
Abruzzo Region. The number of prescriptions per youth ranged from 3.87 in Emilia 
Romagna, to 5.36 in Abruzzo. The incidence was more homogenous and ranged from 
0.86‰ (95% CI 0.78-0.93) in the Veneto Region, to 1.27‰ (95% CI 1.20-1.35) in the Lazio 
Region. The hospital admission  rates ranged from 0.60‰ in Lazio (95% CI 0.55-0.65) to 
3.83‰ (95% CI 3.54-4.11) in Friuli Venezia Giulia. 
 
 
 
Figure 5 – Choropleth map of the participating regions and LHUs. The values of 
prevalence were categorized into three classes calculated on the basis of the mean±1 sd 
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Risperidone was the most prescribed psychotropic drug in five out of seven regions. The 
only two active substances that were among the 10 most prescribed in all regions were 
risperidone and sertraline. In fact, risperidone, along with methylphenidate and paroxetine, 
were among the 10 most prescribed active substances in six out of seven regions. 
The Welch’s ANOVA analysis found a significant difference between regions in the 
prevalence by LHUs (F= 3.16, p=0.03). The post-hoc analysis found a significant difference 
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between the prevalence of Friuli Venezia Giulia and Emilia Romagna regions (mean 
difference= 0.57‰; 95% CI 0.01-1.12). There was no significant correlation between 
prevalence and prescription rates (RP=0.05; p=0.66), latitude (RP=-0.10; p=0.42), longitude 
(RP=0.17; p=0.16), average annual income (RP=0.10; p=0.42) or hospital admission rates 
(RP=0.21; p=0.08). 
 
c. Temporal trend 
The overall prevalence of psychotropic drug prescription from 2006 to 2011 was stable, and 
no significant trend was found (χ2t= 0.001 p=0.97). There was a slight increase in 
antipsychotic prevalence (χ2t= 32.4; p<0.001) from 0.60 to 0.69‰, and a decrease in 
antidepressants prevalence (χ2t= 187; p<0.001) from 1.26 to 1.02‰. An increase was 
observed in ADHD medication prevalence (χ2t= 1065; p<0.001), from 0.01 to 0.19‰, Table 
9. 
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The incidence of new psychotropic drug users decreased from 2006 to 2011 (χ2t=60,3 
p<0,001) from 1.15 to 1.03‰. The same trends were observed in the incidence of new 
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users considering antidepressants, while an increase was observed in antipsychotics and 
drugs for ADHD. 
There was a significantly increasing trend in psychotropic drug prevalence in Friuli Venezia 
Giulia, from 1.68 to 2.17‰, and Veneto, from 1.30 to 1.57‰ (respectively χ2t= 14.3 and 
χ2t=31.6; p<0.001), while a slightly decreasing trend was present in Emilia Romagna (χ2t= 
5.27 p=0.021) with the prevalence shifting from 2.16 to 1.98‰. The prevalence observed in 
the other regions did not show significant trends. 
The hospital admission rate decreased slightly (χ2t= 5.30 p=0.02) from 1.49 in 2006 to 1.44 
in 2011.  
 
4. Discussion 
This is the largest pharmacoepidemiological study evaluating psychotropic drug 
prescription in the Italian paediatric population, including multiple regions and covering 
half of the Italian population of this age. 
Considering the 2011 data, the overall prevalence found was very low compared to those 
from epidemiological studies in most other countries [26,79,81,82,90,94-107]. In particular, 
prevalence of prescription of stimulants in Italy were much lower than that of other regions 
of the world. Stimulants were prescribed to 0.19/1000 children less than 18 years in Italy, 
and to 42/1000 children in the United States who were commercially insured. Prevalence of 
prescription of other medications in other countries to children (<18 years) is shown in 
Table 10. 
 
 
 
 
80 
 
Table 10 - Prevalence (‰) of antidepressants (AD drugs), antipsychotics (AP drugs), and ADHD 
medications observed in ≤ 18 years old in western countries in the last ten years. Data concerning 
Italian children are reported in bold characters.  
Country AD drugs AP drugs ADHD drugs 
USA  27-38 (New England  
2007-2010)1 
16 (Mid-Atlantic states, 
Medicaid, 2012) 
7-26 (2007-2010)1 
49.5 (2008) 
30.5 (2013) 
42-77 (2007-2010)1 
 
UK 11 (2012) 
4.9 (2015)3 
0.77 (2005) 9.2 (2008)2 
7.4 (2008)4 
5.11 (2013)5 
 
Germany 4.8 (2012) 
2 (2012) 
2.1 (2011) 
 
3.2 (2012) 
3.1 (2012) 
2.6 (2011) 
19.1 (2012) 
 
The Netherlands 2.0 (2005) 
6 (2012) 
6.8 (2005) 21 (2007)6 
 
France 3 (2010) 3 (2010) 
4.9(2013)7  
2 (2010) 
 
Denmark 2.67 (2010) 
10 (2012) 
2.05 (2010) 7.29 (2010) 
10 (2008-2012) 6 
 
Iceland n.a. n.a. 12.5 (2007) 
33 (2008-2012) 6 
 
Finland 5.93 (2005) n.a. 1.2 (2007) 
5 (2008-2012) 6 
 
Sweden n.a. n.a. 2.5 (2007) 
12 (2008-2012) 6 
 
Norway 7.0 (2010) 
5.9 (2014) 
 
1.9 (2014) 4.7 (2007) 
14.8 (2014) 
14 (2008-2012) 6 
Canada 15.4 (2007) 7.4 (2008) 21 (2007) 
38 (2011) 7 
 
Ireland 2.61 (2008)5 n.a. 8.63 (2011) 1 
Japan 4.2 (2008-2010) 8.0 (2008-2010) 3.0 (2008-2010)  5 
Israel n.a. 
 
n.a. 49 (2011) 6 
Italy 1.02 (2011) 0.70 (2011) 0.19 (2011) 
1 prevalence for commercially-insured patients (lower value) and Medicaid-insured patients (higher value) 
2 6-12 years old 
3 3-17 years old   
4 13-17 years old   
50-15 years old   
6 6-17 years old  
7 1-24 years old  
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Several reasons for the different prevalence of psychotropic prescriptions between 
countries have been proposed in the literature, the most common of which are differences 
in policy, regulation, and access to mental health services [88,89]. Other important factors 
are cultural (i.e. perceived misuse of psychotropic medication in youths, possible adverse 
effects, etc..), but also include the role of non-pharmaceutical alternatives, and, ultimately, 
the uncertainty of indications (i.e. difficulty in deciding where to place cut-offs for the 
prescription of a drug) [89]. The observed, quite homogeneous and limited, prescription of 
psychotropic medications could be due to a generalised concern about psychotropic 
medications in children, at least in Italian parents [88]. For the same reasons, non-
pharmacological treatments might be preferred in Italy, where drug therapy is reserved 
only to a small fraction of the children attending mental care services [27]. On the other 
hand, a study conducted in the Lombardy Region, showed that the majority of adolescents 
receiving antidepressant drugs were not followed by a child and adolescent psychiatrist, 
and this is clearly alarming [27]. 
A previous multiregional study that used a different database and sample population 
already analysed psychotropic drug prescriptions in Italian youths, in the 1998-2004 period 
[78]. By merging data from the two studies the prevalence of psychotropic medications was 
found to increase in 2001 and reach 3.08‰ in 2002 [78], to then decrease to 1.76‰ in 
2006, and to afterward remain quite stable. After the statement about the increased risk of 
suicidal in adolescents receiving SSRIs, the amount of psychotropic drugs relevantly 
decreased. The plateau trend observed in the years afterwards is different from what was 
observed in other countries, where psychotropic prevalence, especially antidepressants, 
started to climb again, this fact is discussed further later on [80,82,94,100-105]. Even if we 
have no data to demonstrate this, we can speculate that the safety issue about SSRIs 
further increased the suspiciousness about paediatric psychotropic drug treatment and 
prevented the prevalence to reach the levels observed in the previous years like in other 
countries. 
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The analysis of prevalence by age and gender shows different utilization patterns among 
males and females, which somewhat reflect the differences in terms of prevalence of 
mental diseases, with antipsychotics and ADHD medications prescribed more in males at all 
ages, and antidepressants prescribed more in adolescent females. Although the amount of 
psychotropic drug prescriptions in Italian children is limited, a majority is represented 
essentially by antidepressant prescriptions for adolescent females. 
Considering the single classes, there was a decreasing prevalence of antidepressants, and a 
large increase in the prevalence of drugs used for ADHD. The reasons behind the large 
increase in ADHD medications is that the marketing authorization of methylphenidate and 
atomoxetine in Italy was granted in 2007. The prevalence in 2011, however, is still very low 
compared to other countries [81-85,108]. The limited prescription of ADHD medications is 
partly due to the fact that in Italy the prescription requires strict diagnostic assessment and 
continuous monitoring [109,110]. Drugs can be prescribed by child psychiatrists with 
expertise in ADHD treatment, after a standardised diagnostic process [109]. It is also 
possible that the prevalence of ADHD might be lower than in other countries. In fact, in 
recent studies the prevalence of ADHD ranged from 0.5% [110], considering only those 
patients accessing child psychiatric services, to about 1% (surveys) [111,112].  Moreover, 
Italian youths with ADHD tend to be treated more frequently with non-pharmacological 
approaches, and, only in case of severe impairment, with a pharmacological treatment. A 
recent survey estimated that about 1 in 4 children with diagnosed ADHD receives drug 
therapy [109].  Furthermore, in Italy there are not external determinants that may increase 
pressure on drug prescription such as school,  or insurance, like in other countries. 
Despite their decreasing prevalence, antidepressants are still the most prescribed class of 
psychotropic medication, especially in adolescents. The negative trend observed could be 
partly explained by the fact that in Europe the warning concerning the higher risk of suicidal 
behaviour in adolescents treated with some SSRIs was issued in April 2005 [113], which was 
the beginning of our observation period. Nevertheless, the observed data are in contrast 
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with what is shown in other European countries concerning antidepressant prescription in 
youth. In fact, for example, in Denmark there was a linear increase in the prevalence from 
1996 to 2010 [93], and in UK [114] and Germany [90] there was a decrease only in the years 
around the 2002-2006 period (and was very marginal in Germany), after which prevalence 
rose again. The overall prevalence observed in this study is twofold lower than that in 
Denmark and UK in the same years, and about five fold lower than the prevalence observed 
in Germany.  
The most prescribed antidepressant was sertraline, which is approved for obsessive-
compulsive disorder in children older than 6 years of age. The data are different from 
Germany, for example, where the most prescribed antidepressant in all age groups was 
fluoxetine [90].  
In comparison with recent studies showing large increases in the use of antipsychotics in 
youths worldwide [93,115-118], a modest increase in the study period was observed. 
Risperidone was the most prescribed antipsychotic, as well as the most prescribed 
psychotropic medication in the overall population and in school-aged children. In Italy 
risperidone is approved for conduct disorder, and is used mostly to treat autism related 
symptoms, in particular aggressive behaviour.  
Four out of the ten most prescribed psychotropic drugs were prescribed off-label by age: 
three SSRIs (paroxetine, escitalopram, and citalopram) and one antipsychotic (olanzapine). 
Besides these drugs, also pimozide and haloperidol are not approved in youths in Italy, 
amitriptyline is approved for adolescents older than 12 years of age, and aripiprazole for 
those older than 15. These drugs were, nevertheless, among the ten most prescribed in 
school-aged children. Similar results in terms of off label use were observed in other 
international studies [119-121]. 
When looking at the geographical distribution of psychotropic drug prescriptions no 
clusters were identified. At the regional level, the most relevant difference was between 
Friuli Venezia Giulia and the rest of the regions, and, when comparing the distribution of 
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prevalence at the LHU level by regions, only a tiny statistical difference was found. The 
prevalence of psychotropic drug prescriptions did not correlate with latitude or longitude, 
nor with annual income. On the contrary, a North-South trend and an inverse correlation 
between prevalence and annual income was found in studies evaluating the pattern of 
prescription of antibiotics and antiasthmatics [6,8]. 
In particular, when comparing the regional distribution of overall prevalence of drug 
prescription observed in a previous study [122] with the prevalence of psychotropic 
medicines no correlation is found. This fact suggests that psychotropic prescribing pattern 
is different from that of others medicines prescribed in youths. It is likely that local 
differences in cultural factors, prescribing attitude, and environmental setting play a less 
important role in psychotropic drug prescription compared to other, more widely used, 
drug classes. These facts strengthen the hypothesis of a more homogeneous, or differently 
distributed, prescribing attitude concerning psychotropic drugs. Since in this study the 
diagnoses corresponding to each prescription was not available, we compared the 
psychotropic drug prevalence and hospital admission rates for psychiatric disorders at the 
regional level in order to investigate a possible correlation. The correlation was not found, 
hence we could deduce that the regional differences observed in the epidemiology of 
severe psychiatric diseases alone may not explain the differences in drug prescriptions, but 
other factors may play a role. 
Looking at the distribution of active substances by region, it was quite unexpected that only 
four active substances (risperidone, sertraline, methylphenidate, and paroxetine) are 
among the ten most prescribed in six out of seven regions, and only risperidone and 
sertraline are among the most prescribed in all the regions. This geographic variability in 
the choice of psychotropic medicines is particularly evident for SSRIs, and is probably due to 
prescriber attitude (e.g. medical specialty) and to local variability in the marketing of 
different active substances. However previous studies showed that in Italy about 3 out of 4 
antidepressant prescriptions to children and adolescents are filled by GPs without the 
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supervision of a child and adolescent psychiatrist [27,91]. It is, therefore, likely that GPs 
prescribed to adolescents the same active substances they are used to prescribe in adults. 
It is striking that paroxetine, which is not approved for use in youths, is among the most 
prescribed active substances in six out of seven regions, while fluoxetine, which is approved 
for major depressive disorder in children older than eight years of age, is not. 
The major strength of this study is the fact that it is a large multiregional study, and that the 
regions included were representative of different socio-demographic and geographic 
settings, and covered about half of the Italian paediatric population. Some limitation must 
be considered, however.  We were able to include only seven regions and not the overall 
paediatric Italian population, however we included a representative sample of regions 
belonging to different geographic areas and with different socio-economic backgrounds. It 
would be plausible to state that in our sample the South of Italy is a bit under-represented, 
however the two regions included almost 40% of the overall South population. 
Since we used drug prescription as a proxy of pharmacological treatment, it was not 
possible to assess if the drug was actually consumed by patients, and this is a limitation. 
However this limitation do not influence the results of the study, since its aim was to 
monitor prescribing, and not consumption trends.  Another possible limitation is the fact 
that only reimbursed prescriptions were included, excluding out-of-pocket dispensation 
and those filled by private practices. However, these phenomena are likely to be negligible 
for reimbursed drugs. Anxiolytics, sedatives, and hypnotics were not retrieved in the 
database used for this study, leading to an underestimate of the overall prevalence. 
However, this class of drugs should not account for a large proportion of psychotropic drugs 
in children, as shown in a recent Danish study [93]; the underestimate should therefore be 
marginal. Nevertheless, the prevalence of each single class of psychotropic drugs is lower in 
Italy than in other countries, as previously described. Information on the diagnosed 
diseases for which a drug was prescribed was not available, and precluded any evaluation 
of the appropriateness of prescribing. This is, however, an intrinsic limitation of most 
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pharmacoepidemiological studies using prescription databases. Some data were not 
available concerning the Abruzzo Region, as described in the methods section, leading to 
the exclusion of youths living in the Abruzzo Region for the temporal trend analyses. 
 
5. Conclusions 
In this large pharmacoepidemiological study including about half of the Italian youth 
population, the prevalence of psychotropic drugs observed was substantially lower than in 
other countries and remained stable during the observation period. No significant clusters 
were found in the geographic distribution of psychotropic drug prescriptions, differently 
from what was observed for other classes of medicines, showing a quite uniform, limited 
prescription of psychotropic medications.  
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VI. Quality of drug prescribing in paediatrics 
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A. Review of Italian primary care paediatricians identifies 38 commonly prescribed 
drugs for children 
1. Introduction 
Children are one of the patient populations most exposed to drugs [3]. Wide qualitative and 
quantitative differences have been documented in the international literature, and within 
countries and regions, that are most likely not due to differences in the epidemiology of 
diseases [6,12,20]. A wide range of drugs is prescribed for Italian paediatric patients, but 
there are only a limited number of active substances that are commonly prescribed by the 
majority of FPs [123]. This is due to differences in prescribing attitudes and different 
geographic and socio-cultural settings, as well as to the marketing of me-too drugs, which 
are compounds with the same mechanism of action as an existing, approved chemical 
entity. These drugs, in most cases, do not bring real advantages to patients when compared 
to the standard treatments [124]. In developed countries the availability of a large amount 
of active substances, often with overlapping indications, may lead to confusion and 
difficulties in choosing the most suitable pharmacological treatment [125].  
The World Health Organization (WHO) defines essential medicines as those needed in a 
basic healthcare system. Such drugs should be able to fulfil essential medical needs and are 
included in the EMLC by considering prevalence of diseases, efficacy, safety and cost 
effectiveness [126,127]. The WHO estimated that, even with large differences among 
countries, half of the prescriptions filled worldwide could be inappropriate [128]. It has 
been demonstrated that clinicians often have to choose between a very large number of 
drugs for a certain condition and that these complex decisions reduce the possibility of 
making a rational choice and increase the risk of inappropriate prescriptions [129,130].  
Prescribing based on a defined list of the best drugs available, excluding less effective and 
more toxic drugs, could reduce the rates of inappropriate prescriptions [131]. However, the 
EMLC represents a minimal list of drugs needed for priority conditions at the worldwide 
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level, and is thus not applicable to any specific country, since countries may have different 
medical needs and priorities. An acknowledged formulary of drugs for children is still 
unavailable at the European level and the most used paediatric formulary is the British 
National Formulary for Children.  
The aim of this observational study was to identify a list of drugs commonly prescribed by a 
reference group of Italian FPs during their daily clinical practice. This group has been 
involved in educational initiatives concerning care and appropriate prescribing for years.  
 
2. Methods 
a. Data source 
The survey group comprised of 64 FPs, who worked in the northern part of the Lombardy 
Region of Italy and each cared for a similar number of patients. The paediatricians were a 
small group of paediatricians near Milan part of an Italian cultural association of 
paediatricians called ACP known by our laboratory since a decade for their initiatives on 
enforcing guidelines on the appropriateness of prescribing. 
The period of observation was from 2 April to 1 June 2012. The participating FPs 
systematically recorded, in electronic medical records, all the cartons of drugs prescribed in 
the primary care clinic, indicating those recommended by a specialist (S).  
The trade names of the drugs and the number of cartons prescribed were collected using 
two different software programmes (Junior bit® and Infantia 2000®), which were those 
commonly used by the FPs for electronic case reports. Drugs were subsequently classified 
according to the Anatomical Therapeutic Chemical classification system, aggregated into 
therapeutic subgroups and divided according to whether the cost was reimbursed: class A 
drugs reimbursed by the NHS, class C drugs not reimbursed by the NHS and over-the-
counter (OTC) drugs. 
90 
 
The outcome measures were the number and percentage of cartons prescribed for each 
active substance and therapeutic subgroup. For each active substance we calculated the 
percentage of prescribers, defined as the percentage of FPs prescribing at least one carton 
of the drug during the study period,  and the percentage of prescriptions based on the 
recommendation of a specialist.  
When prescriptions were recorded on the INFANTIA 2000® software, it was possible to 
distinguish between branded and generic drugs and to identify the formulation. Drug 
formulations were divided into oral use, which comprised tablets, capsules, and oral 
solution/suspensions, and rectal, topic, injectable and inhalator use.  
Drugs included in the list of commonly prescribed drugs were those: 1) prescribed by  50% 
or more of the FPs following their own clinical assessment; 2) for which ≥ 50% of cartons 
were prescribed according to the recommendation of a specialist and prescribed by ≥ 25% 
of FPs. Aggregated and anonymous data were provided and, therefore, ethical approval 
was not required.   
 
3. Results 
A total of 381 active substances were prescribed and these were classified into 70 
therapeutic subgroups. Of these, 183 were classified as class A, 107 as class C and 91 as 
OTC. The 10 most prescribed active substances covered more than 60% of the cartons 
(Table 11).  
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Table 11 – List of medicines prescribed by ≥ 50% of FPs and percentage of prescriptions  
 
Active substance        Prescriptions Prescribers 
 
       n. (%) n. (%) 
amoxicillin 8.879 25.1 64 100.0 
salbutamol 1.516 4.3 64 100.0 
amoxicillin clavulanate 3.255 9.2 63 98.4 
cetirizine 3.199 9.0 63 98.4 
betamethasone 1.075 3.0 63 98.4 
beclometasone 1.224 3.5 60 93.8 
oral aciclovir 688 1.9 60 93.8 
fluticasone 536 1.5 59 92.2 
clarithromycin 653 1.8 57 89.1 
azithromycin 770 2.2 54 84.4 
budesonide 335 0.9 53 82.8 
ophthalmic tobramycin 322 0.9 53 82.8 
levocetirizine 464 1.3 52 81.3 
valproic acid 624 1.8 49 76.6 
cefixime 495 1.4 49 76.6 
montelukast 322 0.9 49 76.6 
ibuprofen 311 0.9 49 76.6 
oxatomide 181 0.5 48 75.0 
paracetamol 638 1.8 43 67.2 
cefpodoxime 447 1.3 43 67.2 
cefaclor 358 1.0 42 65.6 
flunisolide 277 0.8 42 65.6 
cholecalciferol 734 2.1 41 64.1 
macrogol 135 0.4 41 64.1 
mebendazole 111 0.3 40 62.5 
desloratadine 192 0.5 38 59.4 
prednisone 174 0.5 38 59.4 
salmeterol combinations* 158 0.4 38 59.4 
betamethasone+gentamycin derm. 146 0.4 36 56.3 
ophthalmic ketotifen  133 0.4 36 56.3 
paracetamol combinations † 72 0.2 35 54.7 
mometasone 138 0.4 32 50.0 
iron compounds (III) 85 0.2 32 50.0 
other 6,734 19.0 / / 
Total 35,381 100.0 / / 
grey cells = non reimbursable drug 
* other drugs for obstructive airway diseases  
† excluding psycholeptics 
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Each FP prescribed a median of 52.5 (25-104) active substances. A total of 35,381 cartons of 
drugs were prescribed during the observation period: 30,288 (85.6%) were class A, 2,582 
(7.3%) were OTC, and 2,511 (7.1%) were class C.  
Systemic antibiotics (43.8% of the cartons), anti-asthmatics (12.9%) and antihistamines 
(11.8%) were the most prescribed classes. The most prescribed active substances were: 
amoxicillin (25.8% of cartons), amoxicillin clavulanate (9.2%), and cetirizine (9.0%).  The 
number of active substances in the most prescribed therapeutic subgroups, is reported by 
percentage of prescribers (Table 12). 
 
Table 12 – Distribution of active substances among therapeutic subgroups ordered by 
percentage of prescribers. Only classes with at least one active substance prescribed by ≥ 
50 % of FPs were included.   
Therapeutic subgroup Active substances 
<50% 50-74% ≥75% total 
antibiotics (J01) 22 2 5 29 
anti-asthmatics (R03) 6 2 5 13 
antihistamines (R06) 6 1 3 10 
corticosteroids (H02) 3 1 1 5 
antiepileptics (N03)  12 0 1 13 
ophthalmologicals (S01) 31 1 1 33 
NSAIDs (M01) 5 0 1 6 
antivirals (J05) 1 0 1 2 
dermatologic corticosteroids (D07) 16 2 0 18 
analgesics (N02) 2 2 0 4 
vitamins (A11) 6 1 0 7 
other 238 3 0 229 
total 348 15 18 381 
 
The formulation was available for a total of 11,186 cartons of drugs (31.6% of the total), 
prescribed by 17 FPs. The percentages of class A, class C and OTC cartons in this 
prescription subgroup were similar to those observed in the overall sample. The most 
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prescribed cartons were oral formulations (76.6%). In particular, solutions/suspensions 
accounted for 54.8%, tablets/capsules for 21.8%, inhalors for 12.1%, topical drugs for 6.4%, 
injectable drugs for 4.0% and rectally administered drugs for 0.9%. When we looked at the 
five most prescribed active substances, we found that the number of different medicinal 
products prescribed ranged from three for betamethasone to 34 for amoxicillin clavulanate 
and that only one out of three and five out of 34 of these formulations, respectively, were 
prescribed by 50% or more of the FPs.  
In total, 30% (3,361) of the cartons were generic. The rate of generic prescriptions for the 
three most prescribed classes of drugs, was 54.0% for antibiotics, 25.5% for anti-histamines 
and 2.4% for anti-asthmatics. Among the five most prescribed drugs, amoxicillin had the 
highest rate of generic prescriptions (68.5%), followed by amoxicillin clavulanate (47.1%), 
cetirizine (30.0%), and salbutamol (5.9%). There was a high variability of generic use among 
FPs, ranging from 3.2% to 55.6% of cartons prescribed.  
 
a. Prescriptions recommended by the specialist 
During the study period, 57 (89.1%) of the FPs prescribed at least one drug recommended 
by a specialist and a total of 175 active substances, belonging to 52 therapeutic subgroups, 
were prescribed. Of these, 36 drugs were prescribed exclusively based on the 
recommendation of specialists and the most commonly prescribed were: carbamazepine 
(88 cartons), levocarnitine (12), and zonisamide (11). 
The number of cartons recommended by specialists was 2,903 (8.2%) and the most 
recommended classes were antiepileptics (75.5% of the cartons), pituitary and 
hypothalamic hormones and analogues (62.4%), drugs used in diabetes (59.5%) and thyroid 
therapy drugs (58.9%). Valproic acid (382 cartons) and somatropine (246) were the most 
recommended active substances in terms of number of cartons prescribed. 
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b. List of commonly prescribed drugs 
According to the defined criteria, a list of 38 commonly prescribed drugs belonging to 16 
therapeutic subgroups and covering 83.1% of prescriptions was identified. Of these, 33 
were prescribed by 50% or more of the FPs and five were mainly prescribed following the 
recommendation of a specialist (Table 13). 
Table 13 – List of shared medicines identified by the predefined criteria. Therapeutic 
subgroups are ordered by number of packages.  
 
Therapeutic subgroup Active substances 
antibiotics amoxicillin, amoxicillin clavulanate, cefaclor, cefixime, 
cefpodoxime, azithromycin, clarithromycin 
anti-asthmatics salbutamol, salmeterol combinations, beclometasone, 
budesonide, flunisolide, fluticasone, montelukast 
antihistamines oxatomide, cetirizine, levocetirizine, desloratadine 
corticosteroids betamethasone, prednisone 
antiepileptics carbamazepine (R), valproic acid (R), levetiracetam (R) 
ophthalmologics tobramycin, ketotifen 
vitamins cholecalciferol 
analgesics paracetamol, paracetamol combinations excluding 
psycholeptics 
antivirals aciclovir 
dermatological corticosteroids mometasone, betamethasone and gentamicin 
pituitary and hypothalamic 
hormones and analogues  
somatropine (R) 
anti-inflammatories ibuprofen 
antihelmintics mebendazole 
drugs for constipation macrogol 
drugs used in diabetes insulin* (R) 
antianemics iron compounds (III) 
thyroid theraphy levotiroxine (R) 
* and analogs 
(R) ≥ 50% of packages recommended by a specialist 
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4. Discussion 
This observational study evaluated the profile of drugs prescribed during daily clinical 
practice by a group of FPs, who has been involved in healthcare initiatives for a number of 
years. Over 85% of the cartons prescribed were reimbursable. This data is different from a 
previous study in the South of Italy that analysed a sample and found that more than 30% 
were non-reimbursable drugs [132]. The current study shows that, despite the fact that 
non-reimbursable drugs represented more than half of the active substances prescribed, 
only seven of them were commonly prescribed in clinical practice and these were 
paracetamol, ibuprofen, mometasone, betamethasone plus gentamycin, tobramycin, 
ketotifen and macrogol. The high percentage of reimbursable prescriptions indicates that 
the profile emerging from studies using administrative databases of reimbursed 
prescriptions is quite representative of the overall prescribing practice [3,20]. 
This study highlighted that the diseases requiring more drug prescriptions following the 
recommendation of a specialist were chronic illnesses, such as epilepsy, diabetes and a 
number of endocrinological conditions. By using the same approach, on the basis of the 
prescription profile, the diseases that were treated mainly by FPs were infections, asthma 
and dermatological, gastroenterological and ophthalmological conditions. The list of the 
therapeutic areas identified could be used to create a widely acknowledged formulary of 
common paediatric drugs that reflects FPs’ practices. 
The most prescribed active substances were antibiotics, anti-asthmatics and anti-
histamines, as observed in other pharmacoepidemiological studies in children [20,65,133]. 
A 1998 study on paediatric prescriptions in southern Italy showed similar results concerning 
drug classes, with a higher average number of active substances prescribed by FPs [65]. 
Antibiotic prevalence was high compared to that of most of the other European countries, 
but is similar to reports in the literature concerning Italian children [3,6,12,20,22,134].  
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Different medicinal products containing the same drug were used by FPs. The different 
attitudes may be due to the specific preferences of the FP, the influence of marketing and 
the different palatability of formulations [135]. 
The percentage of generic drugs observed in this study (30%) was low when compared with 
those of other European countries (70%) [134], but higher than the percentage in a survey 
on Italian FPs (13.5%)[136]. This is probably due to the fact that FPs involved in educational 
initiatives may be more likely to prescribe generic drugs [22]. However, the data in the 
current study showed that even in a small group of FPs the attitudes towards generic 
prescribing differed widely, indicating that personal preferences exerted a strong influence. 
By using the predefined criteria, we identified a total of 38 active substances necessary to 
fulfil the most relevant clinical needs in the primary care paediatric setting. These data 
confirm the fact that a relatively small number of drugs are used frequently. Of these drugs, 
14 (37%) were included in the EMLC. The difference between our list and the EMLC list is 
partly due to different health needs, priorities and settings, in other words local versus 
global. For example, macrogol is the drug of choice recommended by the NICE, which 
provides the UK NHS with advice on drugs [137], but it is excluded from the EMLC and 
constipation is certainly not a priority condition in countries with scarce resources.  
Besides the incidence and prevalence of diseases, other reasons for the differences 
between the two lists may include high treatment costs, because treatments like 
somatropine are unlikely to be affordable in low-income countries. In addition, regulatory 
or marketing reasons may influence views on how essential drugs are. Betamethasone, for 
example, was prescribed by 63 of the 64 FPs in our study but is not included in the EMLC. 
The WHO, in fact, suggests that prednisolone should be the first choice oral corticosteroid. 
International guidelines on the management of childhood asthma state that oral 
corticosteroids should be used in acute exacerbations when there is a suboptimal response 
to β2-agonists [138,139]. In Italy, however, this recommendation is often not followed and 
these drugs are used mostly to improve symptoms of common URTI, even if there is no 
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evidence of efficacy [140]. Betamethasone has a very low cost in Italy and the formulation, 
small dispersible tablets, means that it can be administered to very young children 
Therefore, this drug is preferred to other oral corticosteroids for asthma and wheezing 
therapy.  
Among the 38 selected drugs, duplications observed in previous studies still persist [123]. 
The presence of four different inhalation corticosteroids (beclometasone, flunisolide, 
budesonide and fluticasone) and two third-generation cephalosporins sharing the same 
posology (cefixime and cefpodoxime) is unlikely to be due to different levels of efficacy. 
Finally, the adoption of a European formulary of paediatric drugs would be helpful in 
promoting a more rational and homogeneous use of drugs in children within countries 
[141]. The rational use of drugs in children is an area of research that has not been 
sufficiently studied and there is a need for interventions to improve it [1]. A formulary of 
the most useful and effective medications for the most common paediatric diseases would 
represent a concrete step towards implementing the rational use of drugs in children. 
Our study has some limitations. It is possible that the list of drugs we identified is not 
applicable to other FPs and geographic settings. In fact, the FPs had similar educational 
levels and motivation and were thus not representative of a broader setting, such as a 
regional or national one. Furthermore, since the role of the FP does not exist everywhere, 
the results may not be applicable to other countries with different systems of paediatric 
care, where GPs treat most children. The observation period lasted eight weeks and a 
longer duration could have identified additional drugs. However, the results are quite 
similar to observations from other paediatric studies [134]. Unfortunately, we were not 
able to collect information concerning the drug dosages and the diseases diagnosed. 
Nevertheless, by looking at the qualitative and quantitative prescription profile, the study 
provides useful insight into the most prominent clinical needs observed in this paediatric 
population.  
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5. Conclusions 
In conclusion, this study allowed the identification of a list of drugs commonly prescribed by 
a group of FPs involved in healthcare initiatives for many years. This shows that 38 drugs 
would be sufficient to treat the most common childhood diseases in this sample of patients.  
Identifying this list of commonly prescribed drugs by this group of experienced FPs could 
provide a good starting point for creating a minimal paediatric formulary that addresses the 
most common clinical needs in the primary care setting.  
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B. Generic antibiotic prescribing in paediatrics 
1. Introduction 
A generic drug is defined as a medicinal product that has the same qualitative and 
quantitative composition in active substance and the same pharmaceutical form as the 
originator. In Italy, when a medicinal specialty is not protected by patent anymore, generic 
drugs are marketed with a 20 to 80% discount in price in respect to the originator. Thus, the 
marketing of generic drugs causes significant savings to the NHS, because the new 
reimbursed price correspond to that of the generic formulation. At the same time, the use 
of generic drugs instead of the brand name alternatives may cause some savings also for 
the citizens. In fact in Italy, if a generic exist for the drug that has been prescribed, the drug 
is fully reimbursed by the NHS only if the patient is willing to buy the generic. If the patient 
is willing to buy the brand name formulation of the drug, then a co-payment is due. 
Generic drugs market is very large in the UK, Denmark, and Germany, representing about 
70% of the cartons sold and about 30% of the expenditure, and generating 13 billion euros 
of savings ( 35 billion euros if considering the entire EU-27)[142]. In USA these percentages 
reached 80% in volume and 20% in expenditure, while in Italy generic drugs represent less 
than 14% in volume, and 7% in expenditure (about 300 million euros) [143]. Despite some 
improvements in the last few years, generic drugs prescribing continues to be limited in 
Italy in respect to other European countries and USA [134]. This difference may be due to 
differences in legislation, cultural factors, and prescribing attitudes.  
Data concerning generic prescribing in paediatrics are scarce. One study conducted in the 
USA in 2002 reported that in under 18 years old about 41% of the overall prescriptions 
were generic drugs [144]. The percentage of generic drugs was higher in analgesics, 
antiasthmatics, and antibiotics (almost 70% of the total). Nowadays, also in paediatrics, the 
prescribing of generic drugs is scarce in Italy. A survey on 303 FPs in 2011 revealed that 
about 29% of the participants believed that generics may contain a lower quantity of active 
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substance compared to the originator [137]. The lack of bioequivalence study in children, 
different excipients, and palatability were indicated as the major issues of generic 
formulations. The FPs included in this study treated with generic drugs less than 20% of 
their patients [137]. An analysis of the prescription database of the Lombardy Region in 
2005 estimated that 41% of children 6 to 13 years old treated with amoxicillin received at 
least one generic formulation of this drug [145]. 
Antibiotics are the most prescribed drugs in children and adolescents, and they represents 
54% of the out of hospital expenditure for drugs in Italy [3,4]. The aim of this study was to 
evaluate generic antibiotics prescribing in paediatrics in the Lombardy Region, and to 
investigate some of the possible determinants. 
 
2. Methods 
a. Data Source 
The data source was the Lombardy Region’s database, which is routinely updated for 
administrative and reimbursement reasons. The database stores all community (i.e. outside 
hospital) prescriptions reimbursed by the NHS. Data were managed anonymously. 
Prescribed drugs were classified according to the Anatomic Therapeutic Chemical (ATC) 
classification system. Antibiotics were defined as all drugs belonging to the J01 ATC 
subgroup. Medicines were considered generic if they were marketed with the INN of the 
active substance.  
b. Study population 
The population included was composed of all children/adolescents <13 years old resident in 
the Lombardy Region, (1,276,932 children/adolescents and 1253 FPs). 15 LHUs were 
included in the study. The sample size of each LHU varied from 12,644 to 160,744 children. 
The population was divided in three groups of age: <1 year old, 1-5 years old, and 6-13 
years old.  
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c. Measures and analysis 
- Prevalence, as the percentage of resident children with at least one prescription in one 
year of observation; 
- percentage of treated children, as the percentage of children with at least one 
prescription of a certain active substance divided by the children treated with antibiotics; 
The association between antibiotic prevalence and the percentage of children treated with 
generic alternatives in the 15 LHUs was evaluated by using the non-parametric Spearman 
rank correlation test.  
With the aim to evaluate the FPs’ prescribing attitude in respect to generic drug 
prescription, FPs were classified into low, mean, and high prescriber on the basis of the 
number of antibiotic prescriptions per patient. A low prescriber showed a mean number of 
antibiotic prescriptions per patient equal to y<x ̅-sd (lower than 0.72), a mean prescriber to 
x ̅-sd<y<x ̅+sd (0.72 to 1.5), and high prescriber to y>x ̅+sd (higher than 1.5). The percentage 
of generic antibiotic prescriptions was compared among the three groups of FPs through 
the non-parametric Krusall-Wallis test, because the distribution of data was not normal, 
and the ANOVA test could not be used appropriately. The Wilcoxon signed-rank test was 
used to compared the generic prescription rate in the different groups of prescribers. The χ2 
for trend was used in order to compare the percentage of children treated with a generic 
formulation in the different age strata. A p-value < 0.05 was considered statistically 
significant. 
 
3. Results 
In 2008, 74 antibiotics corresponding to 813 medicinal specialty were available in the NPF. 
Of these, 339 tablets and capsules, 338 injectables, 136 suspensions for oral use were 
retrieved. For 39 active substances, corresponding to 611 medicinal specialty, a generic 
formulation was available. Cephalosporins (13 active substances), and penicillins (9 active 
substances) were the most represented class. 
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During 2008, 62 different antibiotics were prescribed to 590,940 children (46%) for a total 
of 1,337,236 prescriptions. Prevalence of antibiotic prescriptions was higher in boys than in 
girls (52 vs 48%), and reached the maximum value in children 1 to 5 years old (62%), 
decreasing to 39% in those 6 to 13 years old. 
79% of the overall antibiotic prescriptions concerned antibiotic that had generic 
formulations available on the market (i.e. the patent expired). Generic prescriptions were 
37% of the antibiotic with expired patent, and 29% of the overall antibiotic prescriptions. 
The most prescribed formulations were oral suspensions that represented 88% of the 
antibiotic prescriptions. 86% (n = 509,825) of all the children treated with antibiotics 
received at least one antibiotic with expired patent. The 47% of these children (n = 239,781) 
received at least one generic antibiotic. 
There were no gender differences in the prescription of generic antibiotics. The percentage 
of prescription of generic antibiotics decreased at increasing age: from 47% of children less 
than 1 years old, to 31% in those 6 to 13 years old (χ2t= 18.753; p < 0.001). The most 
prescribed antibiotic was amoxicillin-clavulanate (40% of treated children), followed by 
amoxicillin (22%), and clarithromycin (10%). The 10 most prescribed antibiotics represented 
97% of all the prescriptions for antibiotic drugs. Six of the ten most prescribed active 
substances had an expired patent: amoxicillin clavulanate, amoxicillin, clarithromycin, 
cefaclor, ceftriaxone, and cefuroxime. For these antibiotics generic paediatric formulations 
were available, with the exceptions of cefuroxime and ceftriaxone. 
Table 14, shows the data concerning the four most prescribed antibiotics with expired 
patent. The percentage of prescription of generic antibiotics was 37%, from a minimum of 
6% (clarithromycin) to a maximum of 72% (amoxicillin).  
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Table 14 – Data concerning the four most prescribed antibiotics with expired patent in 
terms of generic drug prescription 
active 
substance 
prescriptio
ns* 
(n) 
patent  
expiration 
(year) 
medicinal specialties* 
(n) 
generics  
(%) 
   total B/G paediatric 
formulations (B/G) 
treated 
childre
n 
prescriptions 
amoxi-
clavulanate 
552,984 2006 10/65 6/6 31.5 26.7 
amoxicillin 283,769 1996 7/40 1/6 71.9 71.5 
clarithromycin 120,360 2008 12/22 6/6 7.4 6.3 
cefaclor 84,889 2002 7/35 5/17 37.2 34.6 
other 50,422 - 54/100 3/17 28.5 28.0 
total 1,062,424 - 90/262 21/52 40.4 37.0 
*Prescriptions concerning active substances with expired patent, B brand name formulation, G 
generic name formulation 
 
a. Prevalence and determinants 
The prevalence of antibiotics varied from 37 to 52% in the 15 LHUs. The percentage of 
prescription of generic antibiotic was the lowest in the Sondrio LHU (12%) and the highest 
in Como LHU (48%). The percentage of children receiving generic amoxicillin followed the 
same trend ranging from 25% in Sondrio LHU, to 83% in the Milano and Como LHUs. A 
correlation between the antibiotic prevalence of prescription and the percentage of 
children treated with generic antibiotics was not found at the LHU level (RS= 0.19; p= 0.49).  
The proportion of generic drugs was higher in FPs prescribing less antibiotics to their 
patients, Table 15. The generic antibiotic prescription rate was lower in high prescribing FPs 
compared to the low prescribing FPs (z= 2.44; p= 0.015), and compared to the mean 
prescribing FPs (z= 2.77; p= 0.005). 
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Table 15 – Comparison of the proportion of generic prescriptions among different groups 
of paediatricians in respect to quantity of antibiotics prescribed 
 
Prescriber N 
Generic prescription (% proportion of 
children ) 
Range mean ± DS 
Low 167 0.0 – 78.5 39.4 ± 20.3 
Mean  842 1.5 – 88.3 39.1 ± 21.6 
High 169 2.9 – 84.5 34.4 ± 22.8 
Total 1,178 0.0 – 88.3 38.5 ± 21.6 
p-value 1   0.015 
  1. Kruskall-Wallis test 
 
4. Discussion 
This study is the first comprehensive analysis of generic antibiotics in paediatrics in Italy on 
a large pharmaceutical database. Despite being limited to the antibiotic class, the analysis is 
quite representative of the prescribing profile, because these drugs are the most used 
medicines in children. Furthermore there are a large number of available generic 
formulations of antibiotic on the paediatric market, and, as confirmed by a survey [137], 
antibiotics are the most commonly prescribed drugs as generics. 
The antibiotic prescription profile observed in this study is similar to that previously 
described in the Lombardy Region and in other Italian regions, and further confirm the 
importance of the geographical determinant, and the higher prevalence in Italy compared 
to other north European countries [3,4,6]. The reasons for this difference are multiple: 
socio-cultural, economic, in the organisation of health systems, and in the physicians’ 
prescribing attitude. 
Generic antibiotic were scantly prescribed in this analysis. Despite the fact that for 6 out of 
10 of the most prescribed antibiotics in children generic drugs were available on the 
market, only 37% of the prescriptions were represented by generic antibiotics, with wide 
differences among geographic areas and FPs. It is remarkable that only for amoxicillin the 
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generic formulations were prescribed more than the brand name ones. For amoxicillin-
clavulanate, the most prescribed drug in Italy in children, generic prescriptions represented 
only 27% of the total, while in the case of clarithromycin the proportion of generic 
formulations prescribed was negligible (6%). These differences may be due only in part to 
the scarce availability of generic paediatric formulations, or to the period immediately after 
the patent expiration. In the case of clarithromycin, the patent expired in 2008, and this 
could explain the very low prescription rate of generic formulation of this drug. 
Nevertheless the very low prescription rate of generic formulations of cefaclor is not 
justifiable neither by patent expiration nor by the lack of availability of paediatric 
formulations. In fact cefaclor patent expired in 2003 in Italy, and 17 generic paediatric 
formulations were available. 
The proportion of children receiving a generic formulation of antibiotics decreased with 
increasing age. This was probably due to the fact that amoxicillin, the antibiotic most 
prescribed as generic formulations, is the most prescribed antibiotic especially in the 
youngest children, due to the epidemiology of acute otitis media.  The prescription rate of 
generic amoxicillin increased compared to 2005 in a similar population, from 41 to 72% [4]. 
This is encouraging and it confirms a trend in a more favourable prescribing attitude 
towards generic antibiotics in FPs. However, wide differences at the local level exist 
regarding the generic prescription rates, with a fourfold difference between the LHU with 
the lowest and the highest values. These differences are not associated with the qualitative 
profile of antibiotic prescriptions, since they persist also when considering only amoxicillin 
alone. Moreover, a correlation between antibiotic prevalence and the prescription rate of 
generic formulations was not found. This result seems to indicate that not necessarily the 
more “virtuous” LHUs in terms of low prevalence of antibiotic prescribed more generic 
formulations. In this regard the Sondrio LHU is emblematic: even being a geographic area 
that has a low prevalence of antibiotic prescription, the prescription of generic antibiotic is 
rare.  
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High prescribers were more likely to prescribe less generic antibiotics compared to low 
prescribers. Most likely this was due to qualitative differences in the prescription profile 
since amoxicillin has the highest prescription rate of generic formulations and other second 
choice antibiotics like cefaclor and clarithromycin are rarely prescribed as generic 
formulations. 
 
5. Conclusions 
The differences among different settings and physicians highlighted the need for 
educational interventions for prescribers and citizens concerning the use of generic 
medicines. In order to be effective these interventions should be part of a more broad task 
of improving rational use of drugs in paediatrics. Furthermore these interventions should 
be undertaken at the local level, especially where generic drug prescriptions is still rare. 
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C. Comparing recurrent antibiotic prescriptions in children treated with a brand 
name or a generic formulation  
1. Introduction 
According to the EMA a generic drug is a medicinal product having the same qualitative and 
quantitative composition in active substances and the same pharmaceutical form as the 
reference medicinal product, and whose bioequivalence with the reference medicinal 
product has been demonstrated to be within acceptable predefined limits [146]. Such limits 
are represented by the AUC and AUCinfinity values ranging from less than 20% to more than 
25% of the brand name drug values (CI 90% 0.8–1.25). A study on food interaction must be 
performed for oral drugs, as well as a study on palatability if there is a paediatric indication 
[146]. Such studies allow the marketing authorisation for the generic product. 
Concerning the effectiveness of generic drugs, scepticism has arisen from both the 
consideration that the efficacy of generic drugs does not need to be proven in order for 
them to be authorised, and from unproven anecdotal reports of non-effectiveness 
[147,148].  One of the drug classes receiving attention due to such anecdotal reports, often 
fostered by marketing campaigns organised by brand name drug producers, is antibiotics. 
Antibiotics are the most used drug class in children, thus effectiveness is very relevant in 
this population of patients. In fact, generic antibiotics are less costly than the trade-name 
products and their increased use generates significant savings for both the patients and 
prescribers, without compromising therapeutic benefits [22,149]. 
A number of post marketing studies have looked at bioavailability of generic antibiotics 
compared with the originators, showing generally favourable results [150-155]. Only a few 
studies reported that generic tablets are sometimes not comparable in vitro to the 
originator product [150] or do not reach bioequivalence [151]. Failing to demonstrate 
bioequivalence because the confidence interval is slightly larger than allowed, however, 
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does not demonstrate lack of clinical effectiveness [152]. Moreover, most post-marketing 
studies demonstrated bioequivalence in clinical trials [153-155]. 
Concerning clinical effectiveness, post-marketing clinical trials are scarce, but showed no 
difference in clinical outcomes when comparing generic and brand name antibiotics 
[155,156]. 
Different paediatric formulations of antibiotics can have a substantially worse palatability 
profile, thus decreasing children’s adherence and possibly increasing therapy failure rates 
[136,157]. Nevertheless, a clinical trial study failed to show significant differences in the 
compliance to oral suspension antibiotics when a brand name or a generic was given [158]. 
In this context, the aim of this study was to investigate the rate of recurrent prescriptions 
and hospital admissions as proxy of therapeutic failure in outpatient children receiving a 
generic/brand name antibiotic prescription by using a pharmacoepidemiological approach. 
The main goal of the study was to indirectly compare the clinical effectiveness of brand 
name and generic formulations of the same active substance in the real setting by using 
prescription data routinely collected for administrative reasons. 
  
2. Methods 
a. The reference price system 
In Italy, the RPS was implemented in 2001. Under the RPS, the NHS reimburses the lowest 
price among the prices of off-patent pharmaceuticals with equal composition in active 
ingredients, with the same pharmaceutical form, method of administration, number of 
units and dosage. If patients refuse the substitution of a medicine with a generic 
alternative, the difference is paid by patients. 
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b. Data source 
The data source was the Lombardy Region’s database, which is routinely updated for 
administrative and reimbursement reasons. The database stores all community (i.e. outside 
hospital) prescriptions reimbursed by the NHS. Data were managed anonymously. 
Prescribed drugs were classified according to the Anatomic Therapeutic Chemical (ATC) 
classification system. Antibiotics were defined as all drugs belonging to the J01 ATC 
subgroup. 
The population included was composed of all children/adolescents <18 years old resident in 
the Lombardy Region, a large Italian region located in the North of the country (1,669,856 
children/adolescents in 2010). The chosen observation period was from 1 February to 30 
April 2010.  
Prescriptions were subsequently divided into index and recurrent prescriptions. 
An index prescription of an antibiotic was defined as any antibiotic prescription that 
occurred during the observational period not preceded by a prescription in the previous 28 
days (for a single child). A recurrent prescription was defined as an antibiotic prescription 
occurring from 1 to 28 days after an index prescription (for a single child). The month of 
May was considered a post-observational period during which only recurrent prescriptions 
were considered (included if a child received an antibiotic prescription in the previous 28 
days). Children receiving more than four prescriptions during the observational period were 
excluded  since they were more likely suffering from a chronic illness. Since a sufficient 
amount of children treated with a generic antibiotic was needed to compare recurrent 
prescription in the generic vs brand name groups of children, only prescription of the 4 
antibiotic with a paediatric generic formulation available since at least two years were 
considered for the analyses (amoxicillin, amoxicillin clavulanate, cefaclor, and 
clarithromycin). 
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c. Therapy switch 
In order to characterise the recurrent prescriptions, for each active substance and for both 
generic and brand name formulations, the percentage of therapy switch was calculated in 
terms of: percentage of different classes and active substances prescribed during the 
recurrence and percentage of brand name vs generic drug prescription.  
 
d. Generic/brand name 
In this study medicines were considered generic if they were marketed with the INN of the 
active substance. In order to evaluate the rate of recurrent prescriptions associated with 
the use of generic/brand name formulations, a list of the most used antibiotics with generic 
formulations was identified. Only antibiotics with paediatric generic formulations that had 
been marketed for more than two years were selected (for which a consolidated use is 
likely): amoxicillin, amoxicillin clavulanate, clarithromycin, and cefaclor. For each active 
substance, for both generic and brand name formulations, and for each age strata, the 
percentage of recurrent prescriptions was calculated. 
 
e. Hospital admissions 
In order to test if a generic or a brand name drug was prescribed, data concerning hospital 
admission were linked with the index prescription occurring in the observational period in 
the same patient. To test this hypothesis, data from hospital discharge records, including 
information on primary diagnoses and up to five coexisting conditions, procedures 
performed and dates of admission and discharge, were retrieved. The diagnoses were 
categorised according to ICD9 (International Statistical Classification of Diseases and 
Related Health Problems). Only primary diagnoses were considered. Hospital admissions 
occurring in the first week of life were excluded and/or those corresponding to the 
following diagnoses: tumors (ICD9 from 140 to 239), epilepsy (343-345), appendicitis (540-
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543), hernia of abdominal cavity (550-553), complications of pregnancy, childbirth, and the 
puerperium (630-677), congenital anomalies (740-759), conditions originating in the 
perinatal period (760-779), and injury and poisoning (800-999). Children/adolescents 
having more than four hospital admissions in the considered period were excluded. For 
each active substance, for both generic and brand name formulations, and for each age 
strata, the percentage of patients with a hospital admission within 28 days following a 
prescription was calculated. Only children with at maximum 4 antibiotic prescriptions and 4 
hospital admissions in the 6 months period were considered for this analyses, because it 
was very complicated to evaluate the different time-windows between more than 8 events 
in 6 months per each child. 
f. Statistical analysis  
Children/adolescents were divided into three age strata: 0-5, 6-11, and 12-17 years old. 
χ2 was used to compare the two main outcomes (percentage of recurrent prescriptions and 
rate of hospital admission) in each age strata in children receiving brand name and generic 
prescriptions. The Cochran–Mantel–Haenszel test was used to compare the main outcomes 
in children receiving brand name or generic prescriptions, taking into account the different 
distribution of events in the three age strata. Statistical analysis was performed using SAS 
software, version 9.2 (SAS, Cary, NC, USA). 
 
3. Results 
In 2010 702,673 children/adolescents (42.1% of the total) received 1,248,570 antibiotic 
prescriptions. During the observational period a total of 329,123 children/adolescents 
received 494,496 antibiotic prescriptions (42.0% of the annual prescriptions). The chosen 
period was representative of the whole antibiotic prescription profile registered during 
2010. Of these children 5,246 were excluded because they received more than four 
prescriptions. 
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Amoxicillin clavulanate, amoxicillin, clarithromycin, cefaclor, azithromycin and cefixime 
were the most used antibiotics and covered 87% of the prescriptions.  A total of 271,697 
children (82.6% of the total) received at least one prescription of the four antibiotics having 
paediatric generic formulations, for a total of 381,720 prescriptions. Amoxicillin clavulanate 
was the most prescribed antibiotic covering 54.8% of these prescriptions, followed by 
amoxicillin (25.4%), clarithromycin (12.6%), and cefaclor (6.2%). The overall percentage of 
generic prescriptions was: 70.4% for amoxicillin, 40.5% for amoxicillin clavulanate, 35.0% 
for cefaclor, and 16.3% for clarithromycin.  
 
 
a. Therapy switch 
  Considering the three most used classes of antibiotics, a therapy switch occurred in 38.1% 
of cases in which the index prescription involved a penicillin, in 55.5% of cases involving a 
cephalosporin, and in 57.5% involving macrolides. The percentage of therapy switches per 
active substance was lowest for amoxicillin clavulanate (46.7%) and highest for cefixime 
(72.1%). The most common recurrent prescriptions involved the same drug prescribed in 
the index prescription for all the active substances considered.  
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When a therapy switch occurred, amoxicillin clavulanate was the most used active 
substance in the recurrent prescription, Table 16.  
The analysis on generic/brand name formulations concerned amoxicillin clavulanate, 
amoxicillin, clarithromycin and cefaclor, since for these drugs paediatric generic 
formulations had been available for at least two years, suggesting a consolidated use. 
During recurrent prescriptions the percentage of generic formulations used was 
substantially the same as that observed in the overall prescription sample. In cases in which 
a generic antibiotic was prescribed as the index prescription, a generic antibiotic was 
prescribed again in about half of the cases, ranging from 47.0% (clarithromycin) to 57.4% 
(cefaclor). When the same active substance was prescribed during a recurrence, there was 
a high percentage of same-type index-recurrent prescriptions (generic-generic and brand 
name- brand name). For generics the percentages ranged from 65.9% for clarithromycin to 
93.6% for amoxicillin, and for brand names they ranged from 86.7% for amoxicillin to 96.2% 
for clarithromycin). 
 
b. Generic/Brand name 
The number and percentage of recurrent prescriptions for each of the four active 
substances, and for generic vs brand name formulations, is reported in Table 17.  
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Table 17 – Number and percentage of recurrent prescriptions among children receiving a 
generic or brand name formulation of the four antibiotics considered. The outcome in the 
two populations was evaluated through a χ2 test. The significant odds ratios and 
confidence intervals are in bold. 
 
 age recurrent prescription χ2 (generic vs brand 
name) 
  generic formulation brand name formulation OR 95% CI 
  N. % N. %   
amoxicillin 0-5 6,732/45,597 14.8 1,769/11,615 15.2 0.96 0.80-1.16 
6-11 1,874/17,172 10.9 1,109/10,103 11.0 0.99 0.70-1.41 
12-17 358/4,338 8.3 598/6,563 9.1 0.90 0.33-2.48 
0-17 8,964/67,107 13.4 3,476/28,281 12.3 0.97* 0.91-1.02 
amoxicillin 
clavulanate 
0-5 6,076/43,507 14.0 8,602/56,563 15.2 0.91 0.87-0.94 
6-11 2,637/23,964 11.0 4,783/39,333 12.2 0.89 0.85-0.94 
12-17 1,004/10,186 9.9 1,737/16,587 10.5 0.94 0.86-1.02 
0-17 9,717/77,657 12.5 15,122/112,483 13.4 0.91* 0.87-0.94 
cefaclor 0-5 832/5,193 16.0 1,328/8,515 15.6 1.03 0.94-1.14 
6-11 252/1,980 12.7 598/4,530 13.2 0.96 0.82-1.12 
12-17 29/196 14.8 96/820 11.7 1.31 0.84-2.05 
0-17 1,113/7369 15.1 2,022/13,865 14.5 1.02* 0.93-1.12 
clarithromycin 0-5 340/2,118 16.1 2,265/16,150 14.0 1.17 1.04-1.33 
6-11 305/2,372 12.9 1,590/12,475 12.8 1.01 0.89-1.15 
12-17 285/2,750 10.4 794/7,736 10.3 1.01 0.88-1.16 
0-17 930/7,240 12.9 4,649/36,361 12.8 1.07* 0.96-1.19 
overall 0-5 13,980/96,415 14.5 13,964/92,848 15.0 0.96 0.93-0.98 
 6-11 5,068/45,488 11.1 8,080/66,441 12.1 0.91 0.87-0.94 
 12-17 1,676/17,470 9.6 3,225/31,706 10.2 0.94 0.88-1.00 
 0-17 20,724 / 
159,373 
13.0 25,269/190,995 13.2 0.96* 0.93-0.98 
 
* Cochran–Mantel–Haenszel test, taking into account the different distribution among age-
strata. 
 
When considering the distribution of events among the three age-strata in the group 
receiving amoxicillin clavulanate, there was a slightly lower rate of recurrent prescriptions 
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in children receiving a generic formulation (OR 0.91; 95% CI 0.87-0.94). A similar, yet not 
clinically relevant, result was observed when comparing the children receiving any generic 
or brand name antibiotic (OR 0.96; 95% CI 0.93-0.98).  
 
c. Hospital Admission 
A total of 3,469 hospital admission occurred within 28 days from an index prescription 
during the observational period. Of these 3,077 (88.7%) occurred in children receiving one 
of the four selected antibiotics. The percentage of overall hospital admissions occurring in 
children treated (as index prescription) with a brand name (1.01%; 95% CI 0.98-1.08%) or a 
generic drug (1.03%; 95% CI 0.96-1.06%) did not differ (χ2=0.543; p=0.43). The number and 
percentage of hospital admissions for each of the four active substances and for generic vs 
brand name formulations is reported in Table 18. When adjusting for events occurring in 
the three different age strata (Cochran–Mantel–Haenszel test), the OR was significant 
(0.86; 95% CI 0.76-0.96) for amoxicillin clavulanate, with a lower percentage of hospital 
admission in patients receiving a generic formulation compared with those receiving a 
brand name one (p=0.002), Table 18.  
When using a composite endpoint (the percentage of children with either a hospital 
admission or a recurrent prescription in both generic and brand name groups) the results 
were similar to those already observed. 
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Table 18 – Number and percentage of hospital admissions among children receiving a 
generic or brand name formulation of the four antibiotics considered. The outcome in the 
two populations was evaluated through a χ2 test. The significant odds ratios and 
confidence intervals are in bold. 
 age hospital admission χ2 (generic vs brand 
name) 
  generic formulation brand name 
formulation 
OR 95% CI 
  N. % N. %   
amoxicillin 0-5 556/39,931 1.39 132/10,475 1.26 1.11 0.91-1.34 
6-11 79/13,872 0.57 40/8,860 0.45 1.26 0.86-1.85 
12-17 27/4,041 0.67 28/6,168 0.45 1.48 0.87-2.51 
0-17 662/57,844 1.14 200/25,503 0.78 1.16* 0.96-1.41 
amoxicillin 
clavulanate 
0-5 443/35,754 1.24 688/46,043 1.49 0.83 0.73-0.93 
6-11 122/19,690 0.62 231/32,280 0.72 0.87 0.69-1.08 
12-17 75/9,456 0.79 118/15,184 0.78 1.02 0.76-1.37 
0-17 640/64,900 0.99 1,037/93,507 1.11 0.86* 0.76-0.96 
cefaclor 0-5 49/4,784 1.02 81/7,800 1.04 0.99 0.69-1.41 
6-11 9/1,756 0.51 14/4,030 0.35 1.48 0.64-3.42 
12-17 1/170 0.59 3/707 0.42 1.39 0.14-13.4 
0-17 59/6,710 0.88 98/12,537 0.78 1.05* 0.74-1.50 
clarithromycin 0-5 26/2,109 1.23 224/15,544 1.44 0.85 0.56-1.28 
6-11 10/2,262 0.44 74/11,499 0.64 0.69 0.35-1.32 
12-17 13/2,622 0.50 34/7,171 0.47 1.05 0.55-1.99 
0-17 49/6,993 0.70 332/34,214 0.97 0.85* 0.57-1.26 
overall 0-5 1,074/82,578 1.30 1,125/79,862 1.41 0.92 0.85-1.00 
 6-11 220/37,580 0.59 359/56,669 0.63 0.92 0.78-1.09 
 12-17 116/16,289 0.71 183/29,230 0.63 1.14 0.90-1.44 
 0-17 1,410/136,447 1.03 1,667/165,761 1.01 0.94* 0.87-1.02 
* Cochran–Mantel–Haenszel test, taking into account the different distribution among age-
strata. 
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4. Discussion 
To the best of our knowledge this is the first pharmacoepidemiological study using a 
database of health determinants to compare generic and brand name antibiotic 
recurrences in children and adolescents.  
The findings did not show any substantial differences in the percentage of recurrent 
prescriptions in children receiving a generic or a brand name formulation when looking 
both at the overall antibiotic prescriptions and the single active substances. In fact, when 
looking at specific active substances and age-strata there are statistically significant 
differences, but when adjusting for age the differences observed disappear. In the case of 
amoxicillin clavulanate the prescription of a brand name formulation seems to be 
associated with slightly higher rates of both recurrent prescriptions and hospital 
admissions. Nevertheless, the absolute differences observed are very small, and not 
clinically significant. In fact, statistical significance is due to a very large sample size, 
especially for the amoxicillin clavulanate group, and, consequently, very narrow confidence 
intervals. Moreover, it is not possible to exclude the presence of susceptibility bias, 
occurring when the treatment regimen selected for a patient depends on the severity of 
the patient's condition. In fact if physicians were, at least in part, biased toward the 
prescription of a generic, they could have more often prescribed the brand name 
amoxicillin clavulanate to patients with the more severe disease at presentation. The 
considerations above are valid also for the group of children receiving any generic antibiotic 
compared to those receiving any brand name antibiotic.  
When taking into account the distribution by age, the number of recurrences and hospital 
admissions were not higher in the generic drug group for any of the antibiotics considered, 
highlighting the fact that children exposed to generics do not appear to be more prone to 
recurrences. The findings are consistent with efficacy outcomes evaluated in previous 
clinical trials involving brand name and generic antibiotic formulations [155,156]. In the 
literature very scant data are available concerning the effectiveness of generic and brand 
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name antibiotic formulations in the outpatient setting. In fact, most studies evaluated 
effectiveness in hospitalised patients, involving carbapenems or piperacillin/tazobactam 
[155, 159-161].  
The general prescription profile is the same observed in other pharmacoepidemiological 
studies that reported data about the same setting and population of patients [20,145]. 
When a recurrence occurred, the same active substance was prescribed again in most 
cases. This finding is not surprising and probably implies that, in most cases, physicians 
were convinced that a longer therapy with the same antibiotic would have been successful. 
Concerning therapy switches, the findings highlighted the fact that amoxicillin clavulanate 
was the most used antibiotic when a recurrence occurred, independently of the active 
substance used as the index prescription. In these cases physicians might be convinced that 
the previous antibiotic course failure was due to beta-lactamase producing bacteria (when 
amoxicillin alone was given).  
In about half of the cases, children receiving a generic drug during the index prescription 
switched to a brand name formulation when a recurrence occurred: this fact may be due, at 
least in part, to the switch in active substance. In fact, different antibiotics have different 
rate 
s of generic use, e.g. the amoxicillin clavulanate generic prescription rate is lower than that 
of amoxicillin. On the contrary, when physicians prescribed the same active substance in 
the recurrence, there was a high concordance of use of generic and brand name 
formulations in the index and recurring prescriptions. It would seems therefore that 
physicians tend not to change their prescribing attitude when the same antibiotic is chosen.  
In Italy generic drug prevalenceis particularly low compared to the rest of Europe, with less 
than one in three antibiotic prescriptions constituted by generic formulations in the 
Lombardy Region, and the percentage is likely to be lower in other regions [162]. Patients’ 
opinions on generic drugs can influence the likelihood of receiving a generic prescription, 
but if their doctor is willing to explain why generic drugs are as effective as the brand name 
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ones the rate of acceptance of drug substitution rises [163]. Unfortunately, in daily clinical 
practice, the physician’s main source of information about drugs are pharmaceutical 
company representatives, and these representatives can greatly influence their perception 
about generic drugs [164]. The literature reports that a significant proportion of physicians, 
especially the older ones, have negative perceptions of generic drugs [164], and this is 
probably the most relevant deterrent to generic prescriptions, also in Italy [137]. Our 
findings are in agreement with most of the literature on generic antibiotics, which states 
that they are a safe [149,156] and economic alternative [22,149] to brand name ones. 
Despite these facts generic formulations continue to be underused, and the reason is likely 
to be biased information on generic drugs [137]. Although the cost analysis of generic vs 
brand name antibiotics was not the goal of the present study, the use of generic antibiotics 
(also in children) is cost-effective [22, 162].  
In order to promote a more rational and cost-effective drug use, new approaches to 
physicians’ education and information about drugs should be undertaken by policy makers, 
promoting a more correct and less biased vision of the generic market among physicians. 
 
5. Strengths and Limits 
This study included a large cohort of children/adolescents, retrospectively followed for 3 
months, including all the reimbursed prescriptions filled by FPs and GPs. The cohort of 
children/adolescents included the total population of a large Italian region, avoiding 
possible selection biases derived from different socio-economic and cultural backgrounds. 
Hospital admissions and composite endpoint analyses were included as a proxy of severe 
disease and therapy failure, showing results in complete agreement with those observed 
during the recurrent prescription analysis. 
Some intrinsic limitations are present given that this is a retrospective observational study. 
A recurrent prescription within 28 days of an index prescription is used in this study as a 
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proxy of therapy failure, and although this is a quite arbitrary period, this approach was 
already used in literature [165]. When looking at recurrent prescriptions, it is possible that 
some were actually relapses (second infection with the same organism) or reinfections 
(different organism), and we were not able to discriminate between them. The previously 
described susceptibility bias could have been adjusted only by knowing the diagnosis and 
the clinical anamnesis, which was not the case. Despite this, it is likely that the diseases, 
including a number of non-recognized viral infections, were distributed evenly between the 
groups of patients receiving a generic or brand name antibiotic, so the results should not be 
influenced.  
Only antibiotics with paediatric generic formulations marketed for more than two years 
were included in this study (amoxicillin, amoxicillin clavulanate, clarithromycin, and 
cefaclor). The four drugs covered 87% of the overall antibiotic prescriptions, the use of 
other generic antibiotics was uncommon, and the comparison with the group receiving the 
brand name alternatives not feasible. We also could not ascertain compliance to treatment 
or if the drug was actually consumed by patients: these are limitations common to all 
pharmacoepidemiology studies using prescription databases. 
 
6. Conclusions 
Findings showed that children initially treated with a generic formulation of the considered 
antibiotics had no different safety and effectiveness outcomes compared to those treated 
with a brand name formulation. The results of the study are in agreement with most of the 
literature on this topic and provide additional evidence on the safety of use of generic 
antibiotics in the outpatient setting, an area that is scantly investigated. The anecdotal  
reports of non-effectiveness are not justified by the data observed in this study and may be 
due to economic interests more than real differences. Policy makers should promote 
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objective information on generic drug use in order to hinder the pressure to prescribe a 
brand name formulation exerted by pharmaceutical representatives on physicians.  
Finally, even if with a few limitations, this study supports the usefulness of routinely 
acquired healthcare data in terms of clinical research potential, even if these results should 
be validated against a gold standard. 
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D. Assessing the  quality of paediatric antibiotic prescribing by community 
paediatricians: a database analysis of prescribing in Lombardy 
1. Introduction 
The lack of appropriate use of antibiotics and antibiotic resistance have been worldwide 
problems for the last few decades [166]. Unnecessary antibiotic prescriptions for viral 
diseases, and the use of second choice therapies for certain conditions, can increase 
antibiotic resistance also in the community setting (i.e. S.Pneumoniae resistance to 
macrolides) [166,167]. Since children are among the most exposed to this drug class, 
rational antibiotic prescribing in paediatrics is of paramount importance [1]. 
Antibiotics are overused in outpatient children in Italy more often compared to other 
European countries [4]. Frequent prescriptions of second choice treatments, and wide 
heterogeneity in prevalence at different geographic area levels (34.0 to 67.9 % among 
healthcare districts) have been identified and described [6,12,122]. Amoxicillin is the first 
line treatment for respiratory infections in children in the community setting, and we 
previously used it as a proxy of appropriateness in Italy ,with large differences in prevalence 
ranging from 8.7% to 28.1% among regions, and from 7.1 to 48.0% among local health units 
[6,168]. The percentage of children treated with amoxicillin was later proposed as an 
indicator of the quality of prescribing (amoxicillin index) by de Bie et al [169].   
The FP’s prescribing attitude has already been identified as one of the main determinants 
of differences in antibiotic prevalence at the area level [12]. Despite this, the association 
between the amount of antibiotics prescribed and the qualitative profile is a scantly studied 
topic. Moreover most epidemiological studies on drug prescription patterns are based on 
administrative databases that rarely contain the indication for the prescription. Thus, 
evaluating appropriateness on a selected population by developing specific quality 
indicators may be a useful proxy for the quality of antibiotic prescribing.  
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The aim of this study was to evaluate the quality of FPs’ antibiotic prescribing through 
administrative databases by analysing a selected population of children and by using 
indicators at the population level.  
 
2. Methods 
a. Data source 
The data source was the database of the Lombardy Region, which is routinely updated for 
administrative and reimbursement reasons. The region is divided into 8 Local Health Units, 
which are further divided into two to seven smaller areas called ASSTs (Social health 
territorial units), for a total of 27 ASST. The three ASSTs referring to the city of Milan are 
considered as a unique ASST in this study. Only drugs reimbursed by the NHS are included 
in the database. Anonymous data were provided by the regional health ministry of the 
Lombardy Region. All drugs were classified according to the ATC system (Anatomical 
Therapeutic Chemical classification system).  
b. Index prescription 
An index prescription was defined as the first antibiotic prescription in 2011 that occurred 
without: an antibiotic prescription in the previous 60 days, a hospital admission in the 
previous 60 days, and an emergency department admission in the previous 14 days.  
c. Inclusion criteria 
Children and adolescents 1-13 years old, cared for a FP, who received at least one index 
prescription during 2011 were included.  
d. Exclusion criteria 
Children who received 7 or more antibiotic prescriptions (95° percentile of the distribution 
of annual prescriptions per children at four years of age, the age with the most antibiotic 
prescriptions) in the 365 days either before or after the index prescription were excluded 
(31,899; 2.7% of the resident population). This criteria ensured that children included in the 
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study were not patients with chronic infections, or with other conditions requiring 
recurrent antibiotic courses. 
Children who were not residents in the Lombardy Region from the year before the index 
prescription until the end of the follow up period were excluded. Children in the first year 
of life were excluded because of possible treatments for bronchiolitis. 
Children who were residents in one of two specific ASSTs were excluded because data on 
emergency department admissions were not available.  
Children who were not cared for by a FP were excluded (59,875; 5.0% of the resident 
population), and those who were cared for by FPs with less than 98 patients (10° percentile 
of the distribution of the number of children per FP) were excluded in order to have a more 
homogeneous population of FPs (1,760 patients; 0.1%). 
Of the 1,002,006 resident children, 424,280 (cared for by 1,164 FPs) satisfied the inclusion 
and exclusion criteria and were included in the study. 
e. Measures 
The percentage distribution of antibiotic prescriptions by class and active substance (for 
amoxicillin and amoxicillin clavulanate) was investigated. 
f. Data analyses 
Each child or adolescent, and FP, was followed for one year from the index prescription.  
The profile of antibiotic prescriptions was estimated at the population level: 
1) at the index prescription;  
2) in unrelated infective episodes, identified by a new antibiotic prescription occurring 30 
days or more after the index prescription.  
g. Quality indicators 
- The A indicator was the proportion of children who received amoxicillin by the FP at the 
index prescription. From the prospective evaluation of data in paediatric ambulatory care in 
Italy it is known that more than half of the systemic antibiotics are prescribed for 
pharyngotonsillitis (26.9%) and acute otitis media (AOM; 24.4%) [170]. In case of bacterial 
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AOM and pharyngotonsillitis, amoxicillin is the first line therapy because, respectively, S. 
Pyogenes (always sensible)[171-173] and S.Pneumoniae (highly sensible in 90% of cases 
[171,174-177]) are the pathogens that are able to cause the most important complications. 
Amoxicillin is the first line therapy also in case of scarlet fever caused by S.Pyogenes (3% of 
antibiotic prescriptions [170]), uncomplicated pneumonia [178,179], and sinusitis 
[170,180]. Hence we estimated that at least 50% of patients treated with an antibiotic 
should be initially treated with amoxicillin (target for the A indicator). 
- The B indicator was the proportion of children who received cephalosporins or 
macrolides, exclusively,  by the FP for every unrelated infective episode. The maximum 
target percentage was set at 10%.  The rationale of this criterion was that self-reported 
hypersensitivity to beta-lactams in children varies from 1.7 to 7.9% [181-183]. We are 
therefore confident that in no more than 10% of children hypersensitivity can justify the 
exclusive prescription of second choice treatments throughout the year. 
Number of FPs that reached the target for the A or B indicators has been estimated also at 
the ASST level. Number of FPs that reached the target for both indicators was also 
estimated.  
The geographical distribution of FPs in respect to the quality indicators was represented in 
choropletic maps. Clusters and outlier values were calculated by using the Anselin Local 
Moran’s I statistic [184]. 
The FPs were categorised based on the distribution of the average number of antibiotic 
prescriptions per patient, considering all their patients ≥1 to 13 years old: low prescriber 
corresponded to the arithmetical mean minus the standard deviation (y<?̅? − 𝑠𝑑 , lower 
than 0.74), a mean prescriber to ?̅? − 𝑠𝑑<y<?̅? + 𝑠𝑑 (0.74 to 1.44), and high prescriber to 
y>?̅? + 𝑠𝑑 (higher than 1.44). The same criteria were used for classifying FPs  in respect to 
age (young  ≤44; adult 45-59; and elderly ≥60), and in respect to number of patients (low 
≤645; mean 646-1,076; and high≥1,077).The quality of prescription (A and B indicators) was 
estimated in the different groups of FPs (low/mean/high prescriber). Cochran-Mantel-
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Haenszel test for trend was used to test the difference among low, mean, and high 
prescribers. A multivariable logistic regression analysis was performed at the FP level on the 
likelihood of reaching the target for both A and B indicators. The FPs’ covariates considered 
were: sex, age, prescribing pattern in respect to quantity of antibiotic prescriptions, number 
of children cared for by each FP, and area of residence. The variables entered the model by 
a stepwise selection with a significance α=0.05. 
The statistical analyses were performed with SAS 9.5, and the cartographic representations 
and spatial analyses with ArcMap 10.5. 
 
3. Results 
Of the 1,002,006 children 1 to 13 years old in our sample, 49.9% received at least an 
antibiotic prescription. Prevalence decreased with increasing age from 63.9% (1 to 5 years 
old) to 30.4% (10 to 12 years old).  
Overall 1,164 FPs cared for a median of 857 children (IQR 736-1012). FPs were mostly 
females (75.3%), and the median age was 53 years old (IQR 48-56). 
 
a. Prescription profile 
Of the 424,280 children included in the study with an index prescription: 146,582 (34.5%) 
received one antibiotic prescription, 115,541 (27.2%) received two prescriptions, and 
162,157 (38.2%) received three to six prescriptions in the year of follow-up. Penicillins were 
prescribed in 68.6%, macrolides in 16.5% and cephalosporins in 13.3% of cases at the index 
prescription. The most prescribed active substance was amoxicillin clavulanate at any age, 
table 19.  
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Table 19 – Percentage distribution of children at the index prescription by active 
substance and age strata 
 
≥1 year 2-5 years 6-9 years 10-13 years Total 
n % n % n % n % n % 
amoxicillin clavulanate 25,858 41.1 91,630 46.0 51,146 46.3 21,699 42.2 190.333 44.9 
amoxicillin 22,350 35.5 46,730 23.4 21,789 19.7 9,696 18.9 100.565 23.7 
clarithromycin 3,286 5.2 15,838 7.9 11,136 10.1 6,581 12.8 36.841 8.7 
azithromycin 2,577 4.1 13,835 6.9 9,885 8.9 6,298 12.3 32.595 7.7 
cefixime 2,499 4.0 8,765 4.4 4,816 4.4 2,368 4.6 18.448 4.3 
cefaclor 2,917 4.6 9,087 4.6 3,602 3.3 817 1.6 16.423 3.9 
cefpodoxime 1,772 2.8 6,797 3.4 3,863 3.5 1,572 3.1 14.004 3.3 
ceftibuten 836 1.3 2,595 1.3 1,237 1.1 423 0.8 5.091 1.2 
fosfomycin 47 0.1 862 0.4 837 0.8 389 0.8 2.135 0.5 
cefuroxime 195 0.3 782 0.4 531 0.5 311 0.6 1.819 0.4 
other 291 0.5 1.087 0.5 786 0.7 711 1.4 2.875 0.7 
> one antibiotic 293 0.5 1.392 0.7 951 0.9 515 1.0 3.151 0.7 
Total 62,921 100 199,400 100 110,579 100 51,380 100 424,280 100 
 
Amoxicillin was prescribed at the index prescription to 23.6% of children, this indicator 
varied widely at the area level ranging from 7.9% to 46.3% among ASSTs. In none of the 
ASST the percentage of children receiving amoxicillin at the index prescription reached the 
target of the 50%. 
A total of 258,681 children (61.0%) had one or more unrelated infection episodes 30 days 
or more after the index prescription. The majority of these children (208,768; 80.2%) 
received different antibiotics during the year; 12.1% of children (31,192) received 
exclusively second choice treatments like macrolides and cephalosporins, and 7.7% 
(19,914) exclusively amoxicillin. These percentages varied widely between ASSTs: from 
8.2% to 22.0% for the former indicator, and from 1.4% to 21.8% for the latter. 
b. Paediatricians 
Each FP prescribed amoxicillin at the index prescription to a median of 21.1% (IQR 9%-37%) 
of patients, and prescribed only non-penicillin antibiotics in unrelated infective episodes to 
9.3% (IQR 6%-14%) of patients. 
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The percentage of FPs who reached the target of having prescribed amoxicillin at the index 
prescription to at least 50% of patients (A indicator) was 12.8%. The percentage of FPs who 
reached the target of having prescribed exclusively non-penicillin antibiotics in unrelated 
infection episodes to less than 10% of patients (B indicator), was 54.0%. Overall, 131 FPs 
(11.3%) reached the target for both indicators (covering 11.2% of the regional child 
population). On the contrary, 518 FPs (44.5%, covering 44.8% of the regional child 
population) showed inadequate quality of antibiotic prescribing, not reaching the target for 
either of the two indicators. 
Table 20 - Distribution of two quality indicators among the FPs ordered by type of 
prescriber  
Type of FP 
Indicator A1 Indicator B2 
Adequate quality 
according to adherence 
to both indicators 
   
No Yes Total % Yes No Yes Total % Yes No Yes Total % Yes 
Low prescriber 121 30 151 19.9 43 108 151 71.5 122 29 151 19.2 
Mean prescriber 751 107 858 12.5 395 463 858 54.0 765 93 858 10.8 
High prescriber 143 12 155 7.7 98 57 155 36.8 146 9 155 5.8 
Total 1,015 149 1,164 12.8 536 628 1,164 54.0 1033 131 1,164 11.3 
p 3 
   
0.002 
   
<0.001 
   
<0.001 
1. FPs who prescribed amoxicillin at the index prescription to at least 50% of their patients 
2. FPs who prescribed only non-penicillin antibiotics in unrelated infective episodes to a 
maximum of 10% of their patients included in the study. 
3. Cochran-Armitage trend test 
 
High prescribers were less likely to prescribe amoxicillin at the index prescription (χ2for 
trend p=0.002), and were more likely to prescribe only non-penicillin antibiotics (χ2for trend 
p<0.001), table 20. The univariable analysis showed that FPs with an adequate quality of 
antibiotic prescribing (reaching the target for both the A and B indicators) were more likely 
to be: low prescribers, males, elderly, and resident in a specific cluster of high values 
identified by the spatial analyses in a urban area in north of Milan, figure 6 and table 21. 
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Figure 6 - Distribution of the FPs that prescribed amoxicillin alone at the index 
prescription to at least 50% of their patients included in the study (A indicator), and of 
the percentage of FPs that prescribed exclusively non-penicillin antibiotics in different 
infection episodes to more than 10% of their patients included in the study (B indicator). 
Spatial cluster analysis of the distribution of the indicators by ASST. 
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Table 21 – FPs characteristics and their association with reaching the target for both the A 
and B quality indicators (adequate quality).  
 
FPs characteristics 
FPs (%) 
adequate quality1 P2 
type of prescriber low prescriber 19.2 
<0.001 mean prescriber 10.8 
high prescriber 5.8 
sex female 9.8 
<0.001 
male 15.6 
age (years) ≤44  4.7 
<0.001 45-59  11.4 
≥60  17.0 
number of patients low ≤645 8.2 
0.031 mean 646-1,076 12.9 
high ≥1,077 7.1 
area of residence urban area at north of Milan3  39.5 
<0.001 
other areas of the region 8.2 
  1.        FPs that reached the target for the A and B quality indicators 
  2.        χ2 test 
   3.       this area includes those that are part of the cluster identified in Figure 6 
 
At the geographic level there was a huge variability in quality of prescribing, with a 
percentage of FPs who reached the target for the A indicator ranging from 0 to 53.0%, and 
for the B indicator ranging from 9.1 to 84.8% between ASSTs, figure 6. In three ASSTs no FP 
reached the targets, and only in one ASST more than 50% of FPs did. 
The multivariable analysis showed that the FP determinants of adequate quality of 
antibiotic prescribing were the geographic factor, being a low prescriber, and being elderly, 
table 4. Sex and the number of patients were not relevant factors in the multivariable 
model, and were excluded by the stepwise selection of covariates. 
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Table 22 – Logistic multivariable regression model for the likelihood of each FP of 
reaching the target for both the A and B quality indicators according to sex, age, 
prescribing pattern in respect to quantity of antibiotic prescriptions, number of children 
cared for by each FP, and area covered by FPs’ offices.  
Covariates OR 1 CI 95% 
type of prescriber 
 
low prescriber 4.61 (1.99 – 10.69) 
mean prescriber 2.26 (1.08 – 4.75) 
high prescriber 1.00 - 
age (years) ≤44  1.00 
 
45-59  2.41 (1.07 – 5.46) 
≥60  3.98 (1.58 – 10.04) 
area covered by FPs’ 
offices  
urban area at north of Milan 2 8.64 (5.47 – 13.66) 
other areas of the region 1.00 - 
1. sex and number of children cared for by each FP did not enter the model according to the stepwise 
selection 
2. cluster of high values identified in Figure 6, according to the Anselin Local Moran’s I statistic 
 
4. Discussion 
To the best of our knowledge this is the first study evaluating the quality of FPs’ antibiotic 
prescribing through an administrative database in Italy. 
In order to reach our objective, we selected, and monitored, children who were receiving a 
course of treatment not preceded by any antibiotic prescription and/or hospitalization in 
the preceding two months. In this regard, we were confident that, at least for the index 
prescription, amoxicillin would be prescribed to the majority of children in our sample. At 
the population level this was not found, and only 24% of children (less than half of 
expected) received amoxicillin as the index prescription. Despite the fact that the Lombardy 
Region is among the settings with a relatively low antibiotic prescription rate in Italy, the 
above findings reveal a poor average quality of prescriptions.  
In other international studies the amoxicillin index was found to be very heterogeneous 
[4,169,185,186], ranging from 21.1% in Germany to 46.8% in the Netherlands, even if in 
Germany phenoxymethylpenicillin appropriately accounts for a significant additional 
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proportion of prescriptions, differently from Italy. First line penicillins were found to be 
scantly prescribed in Italy in a recent study comparing 6 different countries: from 64.8% of 
antibiotic prescriptions in Norway, to 24.1% in the Pedianet database (Italy) and 8% in the 
Lazio Region (Italy) [187]. We were not able to find studies that evaluated the FPs’ quality 
of prescribing at the prescriber level with criteria comparable to those used in our study. 
Only one French study investigated the qualitative profile of community paediatricians at 
the prescriber level, finding cefpodoxime as the most prescribed antibiotic, and amoxicillin 
representing 25% of the antibiotic prescriptions [188]. Other studies evaluated the 
appropriateness of antibiotic prescribing at the population level or comparing different 
type of prescriber [189,190]. In these studies the first-choice antibiotics were prescribed in 
50%-85% of episodes, and there were wide qualitative differences among GPs and FPs 
[189,190]. 
In our study the most prescribed antibiotic was amoxicillin-clavulanate at any age, even 
though it is less palatable and tolerable than amoxicillin alone [191,192]. It is very likely that 
this happens for fear of infections caused by beta-lactamase producing bacteria. This is 
unjustified by the evidence, which shows that beta lactamase producing bacteria in AOM or 
sinusitis, for example, are those causing less severe complications and whose infections 
most commonly resolve spontaneously [174,176,180]. 
Different factors (e.g poor education, parental expectation of a prescription), may explain 
some of the qualitative and quantitative differences between Italy and other countries.It is 
likely that most of the differences observed in our study are due to the FPs’ prescribing 
patterns. We already documented that in the areas where antibiotic prevalence is higher, 
high prescribing FPs are more frequent [12]. In this regard, the current study adds relevant 
findings concerning quality of prescriptions.  
The percentage of FPs with adequate quality of antibiotic prescribing was extremely low, 
and almost half of the FPs did not reach the target for both the A and B indicators. This 
means that almost half of the regional child population was treated with antibiotics that 
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exposed them to greater  potential risks. An impressive variability was found between 
ASSTs, with only one having more than 50% of FPs with good quality prescribing, and three 
ASSTs with no FPs reaching the target . It is quite striking that there were a few FPs who did 
not prescribe the recommended treatment at all at the index prescription to any of their 
patients.  
When looking at the percentage of children receiving second line treatments only 
(macrolides and/or cephalosporins, B indicator) in all the infection episodes, the average 
value was slightly above the threshold expected on the basis of the frequency of beta-
lactams hypersensitivity. Also in this case a huge variability was found between ASSTs, with 
some geographical settings exceeding 20%. Cephalosporins are hardly ever prescribed in 
the community setting in most of the north European countries and do not present 
significant benefits over amoxicillin in most cases [4]. Macrolides are very susceptible to 
developing resistance, and should be used in selected cases, or in hypersensitive patients 
[193]. 
Quantity of antibiotics prescribed was associated with quality. The proportion of FPs 
reaching the target for both indicators was almost fourfold higher in the low prescribing 
group compared to the high prescribing group. Considering, as an additional criteria of 
“good practice”, the limited prescription of antibiotics, only 29 out of 1164 FPs satisfied 
both A and B indicators and were also “low prescribers”. Additionally 146 out of 1164 FPs 
(12,5%) were high prescribers and did not reach the target for the quality indicators. 
Moreover, the Lombardy Region is among the regions with the highest amoxicillin index in 
Italy, it is thus expected that in other regions  the quality indicators at the FP level will be 
worse [4]. 
The study highlighted a specific cluster of higher quality antibiotic prescriptions in an urban 
area slightly north of Milan. This confirms a long term effect of a continuous educational 
intervention (in the period 2004-2008) on a group of FPs in this area that was aimed at 
enforcing the international guidelines for antibiotic treatment of respiratory infections in 
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clinical practice [12,22]. The educational intervention was mainly based on peer 
comparison. The notable persistence is quite remarkable, and is different from the results 
that are usually obtained with educational interventions that are limited in time [194].   
Other factors may be associated with the quality of prescribing, for example socio-
economic factors. We already showed in a multiregional study that antibiotic prevalence is 
higher in low income areas [122]. We compared the amoxicillin index at the ASST level to 
the average annual income per resident, and found that the qualitative profile was likely to 
be worse in low income areas (not shown). However, since the Italian NHS is universalistic, 
being poor or wealthy is unlikely to influence the type of antibiotic prescribed, because 
parents of children don’t have to spend money for antibiotics. Income deprivation in this 
case may be a proxy of cultural deprivation [67]. This correlation should be investigated 
also in countries with private health services. However we believe that prescribing attitude 
is the most crucial factor in the heterogeneity found because, even when looking at the 
same homogenous geographic context, FPs had very different qualitative profiles of 
prescribing. Finally, increasing paediatrician age was one of the factors significantly 
associated with a better quality of antibiotic prescribing. This finding is unexpected, since 
most studies on the association between quality of care and physician age were 
inconclusive or showed that older physician may be at risk of providing lower quality of care 
[190,195,196]. This is an important indication of the need for targeting educational 
interventions especially at the youngest FPs. 
The main weakness of the study is the lack of the diagnoses. We, therefore, were not able 
to evaluate the appropriateness of prescriptions. Nevertheless, real world data concerning 
the access to primary care ambulatories for respiratory infections were used to identify the 
cut-offs for the quality indicators. We were able to analyse only reimbursed prescriptions, 
and not private practice paediatricians. However this fact has a negligible influence on the 
study, since the aim was to investigate the FPs’ quality of antibiotic prescribing. The 
strength of the study is the possibility to compare the results with previous studies in the 
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overall paediatric population in the same region, and to establish the added value of this 
approach. The results showed that the quality indicators proposed, if further validated, may 
be a promising tool for benchmarking the antibiotic prescribing trend at the paediatrician 
level even without knowledge of the diagnoses, and could highlight those prescribing 
behaviours that deviate from the guideline indications.  
 
5. Conclusions 
The quality indicators proposed were able to identify areas of the region, and FPs, with 
inadequate quality of prescriptions. The youngest FPs and those who were not exposed to 
educational interventions showed a significantly worse quality of prescribing. 
FPs who were part of a continuous educational programme on the improvement of 
antibiotic prescribing had a better prescription profile. After further validation, these 
quality indicators could be a surrogate benchmarking tool for comparing the quality of FPs’ 
antibiotic prescriptions, when the diagnosis is unknown, in different settings. 
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VII. Overall discussion and conclusions 
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A. Summary 
Quantitative and qualitative differences were found in drug prescribing in children and 
adolescents between regions and LHUs. Despite the differences, a prescribing profile 
specific to Italy was observed in all the settings, characterised by extensive use of antibiotic 
and anti-asthmatic drugs, and limited use of psychotropic drugs compared to other 
countries. The differences appear to be mainly related to prescribing attitudes in Italian 
physicians but also to other cultural factors and related to the population income.  
 
B. Determinants and relevance 
The geographical factor was one of the main determinants of antibiotic and anti-asthmatic 
drug prevalence. In particular, both lower latitude and income were associated with an 
higher prevalence of antibiotic and anti-asthmatic prescription, but not psychotropic drug 
prescription.  
As we know, income in Italy is associated with latitude, i.e. in the South income is lower. 
However these drugs are fully reimbursed by the NHS, so the reason for this association is 
unlikely to be poverty. It is likely that these two factors may be a proxy for other socio-
economic indicators such as educational deprivation, which is known to be higher in the 
South of the country. However it is very likely that the true cause of the association 
between the increased prevalence in these areas is still unknown since these are ecological 
studies with no individual level data, and a limited amount of covariates available.  
The study on psychotropic drug prescription is the largest ever conducted in Italy. 
Psychotropic drug prescription in paediatric patients is a quite rare event, also strictly 
regulated in the case of ADHD drugs. It is likely that the closed surveillance and monitoring, 
and the need of a more specific disease knowledge for a parent whose child is in need for a 
psychotropic drug, may result in less interference with the physician’s decision of a 
pharmacological treatment. This phenomena may mitigate differences among regions. 
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The research area on the quality of drug prescription, including generic drugs, the study 
about proxies of clinical effectiveness of generic versus brand game antibiotics, and the 
developing of the quality indicators at the paediatrician level is a quite innovative approach 
in this field. From the results of the studies the prescriber’s attitude seems to be the main 
determinant of drug prescribing. The studies showed that high prescribing physicians tend 
to prescribe with a worse qualitative profile, by using less the first line antibiotic 
treatments, and by using more second choice treatments. They also tend to use less generic 
antibiotics. Also, conversely, we found that younger FPs prescribe less recommended 
treatments, and this is quite alarming. 
The review of the literature was the first in this field. The review showed that there was 
indeed an association between parental and offspring drug prescription, at least for some 
kind of drugs, even considering socio-economic and educational confounders which may 
come into play. However the topic is scantly studied, and there is need for more studies in 
particular investigating the association among different drug classes. The hypothesis that 
some authors postulated concerning the possible role of parental stress, anxiety, and other 
kind of psychiatric conditions is quite interesting, and deserves ad hoc studies. 
 
C. Possible priority interventions 
The wide differences observed in terms of quality and quantity of prescriptions between 
and within regions suggest that educational interventions for health care professionals and 
parents may be effective in improving rational drug use. In particular more efforts are 
needed in certain geographical contexts characterised by a low prevalence, but associated 
with inappropriate drug use.  
The findings from this thesis demand more attention and efforts by health policy makers in 
regards to: 
- educational campaigns and local intervention to limit antibiotic prescriptions, especially in 
the South of Italy, but also in some particular areas of the North of the country; 
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- promoting the use of amoxicillin among FPs, that too often prefer amoxicillin clavulanate 
in Italy for fear of beta-lactamase producing bacteria, or other second line drugs such as 
cephalosporins and macrolides; 
- promoting the use of rapid-antigen-detection tests (RADT) and other self-help instruments 
in paediatric ambulatory in order to reduce diagnostic uncertainty, which the literature 
shows to be among the most important factors determining the chance of an antibiotic 
prescription; 
- progressively reducing, and eradicating, the widespread practice of non-evidence based 
treatments such as nebulised steroids for treating symptoms of URTI; 
- promoting a working group on an acknowledged shared formulary in paediatrics, which 
could help in reducing the incredible number of redundant active substances that is 
currently used in the clinical practice; 
- more standardised clinical and therapeutical approaches in the field of paediatric mental 
health among different geographic areas in the country, which could lead to a decreased 
use of off-label active substances in some cases, and an increased use of those treatments 
supported by more solid evidence;  
- promoting generic drug prescription and use, through educational interventions to 
phisycians and citizens stating that they are safe and effective alternatives to brand name 
drugs, and provide sustainability of the NHS;  
 
Finally the studies described in this thesis confirm that pharmacoepidemiology is a valuable 
tool for monitoring drug prescribing and giving indications to policy makers. Merging 
different administrative databases (e.g. prescription, hospitalisation, specialist physician 
databases) maypermit to observe determinants related to prescription attitudes. 
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D. Future perspectives 
In order to overcome the limitations of administrative databases in the future, the study of 
the determinants of drug and other health resources use will continue by setting up a 
prospective birth cohort study. The birth cohort will evaluate the role of maternal and 
young child determinants on the health status during infancy and development. The cohort 
will collect a number of different information concerning birth, familiar characteristics and 
anthropometric information that cannot be obtained by administrative databases.  
Finally, multinational collaborative studies are warranted, with the aim to collect 
representative and comparable data among different countries and different kind of health 
services, in order to improve the rational use of drugs and to guarantee safe and effective 
drug therapies to children and their families. 
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